Bicyclic heterocycles as bet protein inhibitors

ABSTRACT

The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

CLAIM OF PRIORITY

This application is a continuation of U.S. patent application Ser. No.14/554,263, filed on Nov. 26, 2014, which claims priority under 35 USC§119(e) to U.S. Patent Application Ser. No. 61/908,954, filed on Nov.26, 2013, the entire contents of which are hereby incorporated byreference.

TECHNICAL FIELD

The present invention relates to bicyclic heterocycles which areinhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and areuseful in the treatment of diseases such as cancer.

BACKGROUND

The genomes of eukaryotic organisms are highly organized within thenucleus of the cell. DNA is packaged into chromatin by wrapping around acore of histone proteins to form a nucleosome. These nucleosomes arefurther compacted by aggregation and folding to form a highly condensedchromatin structure. A range of different states of condensation arepossible, and the tightness of this structure varies during the cellcycle, being most compact during the process of cell division. Chromatinstructure plays a critical role in regulating gene transcription byregulating protein access to the DNA. The chromatin structure iscontrolled by a series of post translational modifications to histoneproteins, mainly within the tails of histones H3 and H4 that extendbeyond the core nucleosome structure. These reversible modificationsinclude acetylation, methylation, phosphorylation, ubiquitination andSUMOylation. These epigenetic marks are written and erased by specificenzymes that modify specific residues within the histone tail, therebyforming an epigenetic code. Other nuclear proteins bind to these marksand effect outputs specified by this information through the regulationof chromatin structure and gene transcription. Increasing evidence linksgenetic changes to genes encoding epigenetic modifiers and regulatorsleading to aberrant histone marks in diseases such as neurodegenerativedisorders, metabolic diseases, inflammation and cancer.

Histone acetylation is typically associated with the activation of genetranscription, as the modification weakens the interaction between theDNA and the histone proteins, permitting greater access to DNA by thetranscriptional machinery. Specific proteins bind to acetylated lysineresidues within histones to “read” the epigenetic code. A highlyconserved protein module called the bromodomain binds to acetylatedlysine residues on histone and other proteins. There are more than 60bromodomain-containing proteins in the human genome.

The BET (Bromodomain and Extra-Terminal) family of bromodomaincontaining proteins comprises 4 proteins (BRD2, BRD3, BRD4 and BRD-t)that share a conserved structural organization containing tandemN-terminal bromodomains capable of binding to acetylated lysine residuesof histones and other proteins. BRD2, BRD3 and BRD4 are ubiquitiouslyexpressed while BRDt is restricted to germ cells. BRD proteins playessential, but non-overlapping roles in regulating gene transcriptionand controlling cell growth. BET proteins are associated with largeprotein complexes including Mediator, PAFc and super elongation complexthat regulate many aspects of gene transcription. BRD2 and BRD4 proteinshave been shown to remain in complex with chromosomes during mitosis andare required to promote transcription of critical genes including cyclinD and c-Myc that initiate the cell cycle (Mochizuki J Biol. Chem. 2008283:9040-9048). BRD4 is essential for recruiting the proteintranslational elongation factor B complex to the promoters of induciblegenes resulting in the phosphorylation of RNA polymerase II andstimulating productive gene transcription and elongation (Jang et al.Mol. Cell 2005 19:523-534). In some instances, a kinase activity of BRD4may directly phosphorylate and activate RNA polymerase II (Devaiah etal. PNAS 2012 109:6927-6932). Cells lacking BRD4 show impairedprogression through cell cycle. BRD2 and BRD3 are reported to associatewith histones along actively transcribed genes and may be involved infacilitating transcriptional elongation (Leroy et al, Mol. Cell. 200830:51-60). In addition to acetylated histones, BET proteins have beenshown to bind selectively to acetylated transcription factors includingthe RelA subunit of NF-kB and GATA1 thereby directly regulating thetranscriptional activity of these proteins to control expression ofgenes involved in inflammation and hematopoietic differentiation (Huanget al, Mol. Cell. Biol. 2009 29:1375-1387; Lamonica Proc. Nat. Acad.Sci. 2011 108:E159-168).

A recurrent translocation involving NUT (nuclear protein in testes) withBRD3 or BRD4 to form a novel fusion oncogene, BRD-NUT, is found in ahighly malignant form of epithelial neoplasia (French et al, CancerResearch 2003 63:304-307; French et al, Journal of Clinical Oncology2004 22:4135-4139). Selective ablation of this oncogene restores normalcellular differentiation and reverses the tumorigenic phenotype(Filippakopoulos et al, Nature 2010 468:1068-1073). Genetic knockdown ofBRD2, BRD3 and BRD4 has been shown to impair the growth and viability ofa wide range of hematological and solid tumor cells (Zuber et al, Nature2011 478:524-528; Delmore et al, Cell 2011 146:904-917). Aside from arole in cancer, BET proteins regulate inflammatory responses tobacterial challenge, and a BRD2 hypomorph mouse model showeddramatically lower levels of inflammatory cytokines and protection fromobesity induced diabetes (Wang et al Biochem J. 2009 425:71-83; Belkinaet al. J. Immunol 2013). In addition, some viruses make use of these BETproteins to tether their genomes to the host cell chromatin, as part ofthe process of viral replication or use BET proteins to facilitate viralgene transcription and repression (You et al, Cell 2004 117:349-60; Zhuet al, Cell Reports 2012 2:807-816).

Accordingly, there is a need for compounds that modulate the activity ofthe BET family of proteins, including BRD2, BRD3, and BRD4, that can beused to treat BET protein-associated diseases such as cancer. Thecompounds of the invention help meet this need.

SUMMARY

The present invention provides, inter alia, a compound of Formula I:

or a pharmaceutically acceptable salt thereof; wherein the variables areas defined below.

The present invention also provides a pharmaceutical compositioncomprising a compound of Formula I, or a pharmaceutically acceptablesalt thereof, and at least one pharmaceutically acceptable carrier.

The present invention also provides a method of inhibiting a BET proteincomprising contacting a compound of Formula I, or a pharmaceuticallyacceptable salt thereof, with the BET protein.

The present invention also provides a method of treating cancer andother diseases comprising administering to a patient a therapeuticallyeffective amount of a compound of Formula I, or a pharmaceuticallyacceptable salt thereof.

The present invention also provides a compound of Formula I, or apharmaceutically acceptable salt thereof, for use in therapy.

The present invention also provides use of a compound of Formula I, or apharmaceutically acceptable salt thereof, in the preparation of amedicament for use in therapy.

DETAILED DESCRIPTION

The present invention provides, inter alia, a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

represents a single or double bond;

Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl,C₅-cycloalkyl, C₆-cycloalkyl, 5-membered heterocycloalkyl, or 6-memberedheterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 R^(B);

L is absent, —(CR^(a)R^(b))_(p)—,—(CR^(a)R^(b))_(n)—O—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S(═O)₂—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)O—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—OC(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—NR^(c)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)NR—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—NR^(c)C(═O)—(CR^(a)R^(b))_(m)—, or—(CR^(a)R^(b))_(n)—NR^(c)C(═O)NR^(d)—(CR^(a)R^(b))_(m)—;

A1 is CR³ or N;

A2 is C or N;

A3 is C or N;

A4 is CR⁴ or N;

wherein when one of A2 and A3 is N, then the other of A2 and A3 is C;

W is CR⁵ or N;

X is CR⁶ or N;

Y is CR⁷ or N;

Z is C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, or 5-10 membered heteroaryl, or 4-10membered heterocycloalkyl, each of which is optionally substituted by 1,2, 3, 4, or 5 R^(Z);

R¹ is H or C₁₋₄ alkyl;

R² is C₁₋₄ alkyl, C₁₋₄ haloalkyl, or C₁₋₄ hydroxyalkyl;

R³ and R⁴ are each independently selected from H, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl;

R⁵ is H, halo, C₁₋₆ alkyl, or C₁₋₆ haloalkyl;

R⁶ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), S(O)R^(b1),S(O)NR^(c1)R^(d1), S(O)₂R^(b1), or S(O)₂NR^(c1)R^(d1), wherein said C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₄haloalkyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1),C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1),NR^(c1)C(O)R^(b1), NR^(c1)C(O)OR^(a1), NR^(c1)C(O)NR^(c1)R^(d1),C(═NR^(e1))R^(b1), C(═NR^(e1))NR^(c1)R^(d1),NR^(c1)C(═NR^(e1))NR^(c1)R^(d1), NR^(c1)S(O)R^(b1), NR^(c1)S(O)₂R^(b1),NR^(c1)S(O)₂NR^(c1)R^(d1), S(O)R^(b1), S(O)NR^(c1)R^(d1), S(O)₂R^(b1),and S(O)₂NR^(c1)R^(d1);

R⁷ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), S(O)R^(b2),S(O)NR^(c2)R^(d2), S(O)₂R^(b2), or S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₄haloalkyl, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2),C(═NR^(e2))R^(b2), C(═NR^(e2))NR^(c2)R^(d2),NR^(c2)C(═NR^(e2))NR^(c2)R^(d2), NR^(c2)S(O)R^(b2), NR^(c2)S(O)₂R^(b2),NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),and S(O)₂NR^(c2)R^(d2);

each R^(B) is independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), C(═NR^(e3))R^(b3),C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂, OR^(a3), SR^(a3),C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3),NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);

each R^(Z) is independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂,OR^(a4), SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4),OC(O)R^(b4), OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), C(═NR^(e4))R^(b4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4),S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a4), SR^(a4), C(O)R^(b4),C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4), OC(O)NR^(c4)R^(d4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)R^(d4), NR^(c4)C(O)R^(b4), NR^(c4)C(O)OR^(a4),NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4),NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4),and S(O)₂NR^(c4)R^(d4);

each R^(a) and R^(b) is independently selected from H, halo, OH, methyl,and ethyl;

each R^(c) and R^(d) is independently selected from H, C₁₋₄ alkyl, C₁₋₄haloalkyl, C₁₋₄ hydroxyalkyl, and cyclopropyl;

each R^(a1), R^(b1), R^(c1), R^(d1), R^(a2), R^(b2), R^(c2), R^(d2),R^(a3), R^(b3), R^(c3), R^(d3), R^(a4), R^(b4), R^(c4), and R^(d4) isindependently selected from H, C₁₋₆ alkyl, C₁₋₄ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃-C₁₀ cycloalkyl, 5-10 membered heteroaryl,4-10 membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀cycloalky-C₁₋₆ alkyl, (5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10membered heterocycloalkyl)-C₁₋₆ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀cycloalky-C₁₋₆ alkyl, (5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10membered heterocycloalkyl)-C₁₋₆ alkyl is optionally substituted with 1,2, 3, 4, or 5 substituents independently selected from C₁₋₄ alkyl, C₁₋₄haloalkyl, halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5),NR^(c5)S(O)₂R^(b5)NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c1) and R^(d1) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c2) and R^(d2) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5),NR^(c5)S(O)₂R^(b5)NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c3) and R^(d3) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c4) and R^(d4) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c)R^(d5), and S(O)₂NR^(c5)R^(d5);

each R^(e1), R^(e2), R^(e3), and R^(e4) is independently selected fromH, C₁₋₄ alkyl, CN, OR^(a5), SR^(b5), S(O)₂R^(b5), C(O)R^(b5),S(O)₂NR^(c5)R^(d5), and C(O)NR^(c5)R^(d5);

each R^(a5), R^(b5), R^(c5), and R^(d5) is independently selected fromH, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, whereinsaid C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, is optionallysubstituted with 1, 2, or 3 substituents independently selected from OH,CN, amino, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄alkylamino, di(C₁₋₄ alkyl)amino, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

each R^(e5) is independently selected from H, C₁₋₄ alkyl, and CN;

n is 0, 1, or 2;

m is 0, 1, or 2; and

p is 1, 2, 3, or 4;

wherein any aforementioned heterocycloalkyl group, including theheterocycloalkyl group of Ring B, is optionally substituted by 1 or 2oxo groups.

The present invention further provides, inter alia, a compound ofFormula I:

or a pharmaceutically acceptable salt thereof; wherein

represents a single or double bond;

Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl,C₅-cycloalkyl, C₆-cycloalkyl, 5-membered heterocycloalkyl, or 6-memberedheterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 R^(B);

L is absent, —(CR^(a)R^(b))_(p)—,—(CR^(a)R^(b))_(n)—O—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S(═O)₂—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)O—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—OC(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—NR^(c)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)NR^(c)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—NR^(c)C(═O)—(CR^(a)R^(b))_(m)—, or—(CR^(a)R^(b))_(n)—NR^(c)C(═O)NR^(d)—(CR^(a)R^(b))_(m)—;

A1 is CR³ or N;

A2 is C or N;

A3 is C or N;

A4 is CR⁴ or N;

wherein when one of A2 and A3 is N, then the other of A2 and A3 is C;

W is CR⁵ or N;

X is CR⁶ or N;

Y is CR⁷ or N;

Z is C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, or 5-10 membered heteroaryl, or 4-10membered heterocycloalkyl, each of which is optionally substituted by 1,2, 3, 4, or 5 R^(Z);

R¹ is H or C₁₋₄ alkyl;

R² is C₁₋₄ alkyl, C₁₋₄ haloalkyl, or C₁₋₄ hydroxyalkyl;

R³ and R⁴ are each independently selected from H, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl;

R⁵ is H, halo, C₁₋₆ alkyl, or C₁₋₆ haloalkyl;

R⁶ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), S(O)R^(b1),S(O)NR^(c1)R^(d1), S(O)₂R^(b1), or S(O)₂NR^(c1)R^(d1), wherein said C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₄haloalkyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1),C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1),NR^(c1)C(O)R^(b1), NR^(c1)C(O)OR^(a1), NR^(c1)C(O)NR^(c1)R^(d1),C(═NR^(e1))R^(b1), C(═NR^(e1))NR^(c1)R^(d1),NR^(c1)C(═NR^(e1))NR^(c1)R^(d1), NR^(c1)S(O)R^(b1), NR^(c1)S(O)₂R^(b1),NR^(c1)S(O)₂NR^(c1)R^(d1), S(O)R^(b1), S(O)NR^(c1)R^(d1), S(O)₂R^(b1),and S(O)₂NR^(c1)R^(d1);

R⁷ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), S(O)R^(b2),S(O)NR^(c2)R^(d2), S(O)₂R^(b2), or S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₄haloalkyl, CN, NO₂, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2),C(═NR^(e2))R^(b2), C(═NR^(e2))NR^(c2)R^(d2),NR^(c2)C(═NR^(e2))NR^(c2)R^(d2), NR^(c2)S(O)R^(b2), NR^(c2)S(O)₂R^(b2),NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),and S(O)₂NR^(c2)R^(d2);

each R^(B) is independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),OC(O)R^(b3), OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), C(═NR^(e3))R^(b3),C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3), OC(O)NR^(c3)R^(d3),C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)OR^(a3),NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3),NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3),and S(O)₂NR^(c3)R^(d3);

each R^(Z) is independently selected from halo, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂,OR^(a4), SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4),OC(O)R^(b4), OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), C(═NR^(e4))R^(b4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4),S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a4), SR^(a4), C(O)R^(b4),C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4), OC(O)NR^(c4)R^(d4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)R^(d4), NR^(c4)C(O)R^(b4), NR^(c4)C(O)OR^(a4),NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4),NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4),and S(O)₂NR^(c4)R^(d4);

each R^(a) and R^(b) is independently selected from H, halo, OH, methyl,and ethyl;

each R^(c) and R^(d) is independently selected from H, C₁₋₄ alkyl, C₁₋₄haloalkyl, C₁₋₄ hydroxyalkyl, and cyclopropyl;

each R^(a1), R^(b1), R^(c1), R^(d1), R^(a2), R^(b2), R^(c2), R^(d2),R^(a3), R^(b3), R^(c3), R^(d3), R^(a4), R^(b4), R^(c4), and R^(d4) isindependently selected from H, C₁₋₆ alkyl, C₁₋₄ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl,4-10 membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀cycloalky-C₁₋₆ alkyl, (5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10membered heterocycloalkyl)-C₁₋₆ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, 4-10 membered heterocycloalkyl, C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀cycloalky-C₁₋₆ alkyl, (5-10 membered heteroaryl)-C₁₋₆ alkyl, and (4-10membered heterocycloalkyl)-C₁₋₆ alkyl is optionally substituted with 1,2, 3, 4, or 5 substituents independently selected from C₁₋₄ alkyl, C₁₋₄haloalkyl, halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c1) and R^(d1) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c2) and R^(d2) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c3) and R^(d3) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

or any R^(c4) and R^(d4) together with the N atom to which they areattached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl groupoptionally substituted with 1, 2, or 3 substituents independentlyselected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7 memberedheterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆ haloalkyl,halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5), wherein said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 4-7membered heterocycloalkyl, C₆₋₁₀ aryl, and 5-6 membered heteroaryl areoptionally substituted by 1, 2, or 3 substituents independently selectedfrom halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5);

each R^(e1), R^(e2), R^(e3), and R^(e4) is independently selected fromH, C₁₋₄ alkyl, CN, OR^(a5), SR^(b5), S(O)₂R^(b5), C(O)R^(b5),S(O)₂NR^(c5)R^(d5), and C(O)NR^(c5)R^(d5);

each R^(a5), R^(b5), R^(c5), and R^(d5) is independently selected fromH, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, whereinsaid C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, is optionallysubstituted with 1, 2, or 3 substituents independently selected from OH,CN, amino, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄alkylamino, di(C₁₋₄ alkyl)amino, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

-   -   each R^(e5) is independently selected from H, C₁₋₄ alkyl, and        CN;

n is 0, 1, or 2;

m is 0, 1, or 2; and

p is 1, 2, 3, or 4;

wherein any aforementioned heterocycloalkyl group, including theheterocycloalkyl group of Ring B, is optionally substituted by 1 or 2oxo groups.

When both A2 and A3 are C, then the symbol

represents a double bond, and when one of A2 and A3 is N and the otheris C, then the symbol

represents a single bond.

In some embodiments, R¹ is H.

In some embodiments, R² is C₁₋₄ alkyl.

In some embodiments, R² is methyl.

In some embodiments, W is CR⁵.

In some embodiments, X is CR⁶.

In some embodiments, Y is CR⁷.

In some embodiments, Y is N.

In some embodiments, the bicyclic ring containing W, X, and Y isselected from:

In some embodiments, the bicyclic ring containing W, X, and Y isselected from:

In some embodiments, L is —(CR^(a)R^(b))_(n)—O—(CR^(a)R^(b))_(m)—.

In some embodiments, L is O or CH₂O.

In some embodiments, L is O.

In some embodiments, Z is C₆₋₁₀ aryl, C₃₋₇ cycloalkyl, or 5-10 memberedheteroaryl, each of which is optionally substituted by 1, 2, 3, 4, or 5R^(Z).

In some embodiments, Z is C₆₋₁₀ aryl or 5-10 membered heteroaryl, eachof which is optionally substituted by 1, 2, 3, 4, or 5 R^(Z).

In some embodiments, Z is phenyl optionally substituted by 1, 2, 3, 4,or 5 R^(Z).

In some embodiments, Z is

In some embodiments, Z is C₃₋₇ cycloalkyl optionally substituted by 1,2, 3, 4, or 5 R^(Z).

In some embodiments, Z is cyclobutyl.

In some embodiments, R^(Z) is independently selected from halo, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a4),SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4),OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), C(═NR^(e4))R^(b4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4),S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4).

In some embodiments, R^(Z) is independently selected from F, Cl, and Br.

In some embodiments, A1 is CR³.

In some embodiments, A2 is C.

In some embodiments, A3 is C.

In some embodiments, A4 is CR⁴.

In some embodiments, each R^(B) is independently selected from C₁₋₆alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10membered heterocycloalkyl, wherein said C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂, OR^(a3), SR^(a3),C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3),NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);

In some embodiments, each R^(B) is independently selected from C₁₋₆alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl,wherein said C₁₋₆ alkyl is optionally substituted with 1, 2, or 3substituents independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10membered heteroaryl, 4-10 membered heterocycloalkyl, and C(O)OR^(a3).

In some embodiments, each R^(B) is independently selected from C₁₋₆alkyl, C₃₋₁₀ cycloalkyl, and 4-10 membered heterocycloalkyl, whereinsaid C₁₋₆ alkyl is optionally substituted with 1 or 2 substituentsindependently selected from phenyl and C(O)OR^(a3).

In some embodiments, the compounds of the invention have Formula II:

wherein:

the 5-membered ring formed by A2, A3, B1, B2, and B3 is (1) 5-memberedheteroaryl wherein B1, B2, and B3 are each independently selected fromCH, N, NH, 0, and S, (2) C₅-cycloalkyl wherein B1, B2, and B3 are eachindependently selected from CH, CH₂, and C(O), or (3) 5-memberedheterocycloalkyl wherein B1, B2, and B3 are each independently selectedfrom CH, CH₂, C(O), N, NH, O, S, S(O), and S(O)₂; and

q is 0, 1, 2 or 3.

The floating substituent —(R^(B))_(q) depicted in Formula II and otherformulae is meant to indicate that there can be q number of R^(B) groupssubstituted on any of the B1, B2, and B3 components of the A2, A3, B1,B2, and B3 5-membered ring. For example, when B1 is selected as CH, thehydrogen of the CH can be replaced by R^(B) when it is substituted.

In some embodiments, B1, B2, and B3 are each independently selected fromCH, CH₂, C(O), N, and NH.

In some embodiments, B1 is N or NH.

In some embodiments, B1 is NH.

In some embodiments, B2 is N, CH, or C(O).

In some embodiments, B3 is N or NH.

In some embodiments, the compounds of the invention have Formula IIa:

In some embodiments, the compounds of the invention have Formula IIb:

In some embodiments, the compounds of the invention have Formula IIc:

wherein r is 0, 1, 2, 3, 4, or 5.

The floating substituent —(R^(Z))_(r) depicted in the phenyl ring ofFormula IIc and in other formulae herein is meant to indicate that therecan be r number of R^(Z) groups substituted on the phenyl ring.

In some embodiments, the compounds of the invention have Formula IId,IIe, IIf, or IIg:

wherein:

r is 0, 1, 2, 3, 4, or 5; and

R⁸, R⁹, and R¹⁰ are each independently selected from H, C₁₋₆ alkyl,C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, and 4-10membered heterocycloalkyl, wherein said C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₆₋₁₀aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, 4-10 memberedheterocycloalkyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3),C(O)NR^(c3)R^(d3), C(O)OR^(a3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3),NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3),and S(O)₂NR^(c3)R^(d3).

In some embodiments, the compounds of the invention have Formula IId,IIe, IIf, or IIg:

wherein:

r is 0, 1, 2, 3, 4, or 5; and

R⁸, R⁹, and R¹⁰ are each independently selected from H, C₁₋₆ alkyl,C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, and 4-10membered heterocycloalkyl, wherein said C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, CN, NO₂,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3).

In some embodiments, R⁸, R⁹, and R¹⁰ are each independently selectedfrom H, C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, and 4-10 membered heterocycloalkyl, wherein said C₁₋₆ alkyl,C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, and 4-10membered heterocycloalkyl are each optionally substituted with 1, 2, 3,4, or 5 substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆haloalkyl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3),C(O)OR^(a3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3).

In some embodiments, r is 0, 1, 2, or 3.

In some embodiments, the compounds of the invention have Formula IIh:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compounds of the invention have Formula IIi orIIj:

or a pharmaceutically acceptable salt thereof, wherein:

R⁸, R⁹, and R¹⁰ are each independently selected from H, C₁₋₆ alkyl,C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, and 4-10membered heterocycloalkyl, wherein said C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₆₋₁₀aryl, CN, NO₂, OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3),C(O)OR^(a3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3).

In some embodiments, the compounds of the invention have Formula III:

wherein:

the 6-membered ring formed by A2, A3, B4, B5, B6, and B7 is (1) phenyl,(2) 6-membered heteroaryl wherein B4, B5, B6, and B7 are eachindependently selected from CH and N, (3) C₆-cycloalkyl wherein B4, B5,B6, and B7 are each independently selected from CH, CH₂, and C(O), or(4) 6-membered heterocycloalkyl wherein B4, B5, B6, and B7 are eachindependently selected from CH, CH₂, C(O), N, NH, O, S, S(O), and S(O)₂;and

s is 0, 1, 2, 3, or 4.

The floating substituent —(R^(B))_(s) depicted in Formula III and otherformulae herein is meant to indicate that there can be s number of R^(B)groups substituted on any of the B4, B5, B6, and B7 components of theA2, A3, B4, B5, B6, and B7 6-membered ring. For example, when B4 isselected as CH, the hydrogen of the CH can be replaced by R^(B) when itis substituted.

In some embodiments, the bicyclic moiety containing Ring B has theformula:

wherein q is 0, 1, 2 or 3.

In some embodiments, the bicyclic moiety containing Ring B has theformula:

wherein q is 0, 1, 2 or 3.

In some embodiments, the bicyclic moiety containing Ring B has theformula:

wherein q is 0, 1, 2 or 3.

In some embodiments, the bicyclic moiety containing Ring B has theformula:

wherein s is 0, 1, 2, 3, or 4.

In some embodiments, the bicyclic moiety containing Ring B has theformula:

wherein s is 0, 1, 2, 3, or 4.

In some embodiments, the bicyclic moiety containing Ring B has theformula:

wherein s is 0, 1, 2, 3, or 4.

In some embodiments, the bicyclic moiety containing Ring B is selectedfrom:

wherein each of the above formulas can be optionally substituted by oneor more R^(B) on the 5- or 6-membered ring corresponding to Ring B by upto 5 substituents or up to the available substitutable valencies,whichever is less. In some embodiments, A1 and A4 are each CH.

In some embodiments, the bicyclic moiety containing Ring B is selectedfrom:

wherein each of the above formulas can be optionally substituted asvalency allows by one or two R^(B) on the 5-membered ring correspondingto Ring B. In some embodiments, A1 and A4 are each CH.

It is appreciated that certain features of the invention, which are, forclarity, described in the context of separate embodiments, can also beprovided in combination in a single embodiment. Conversely, variousfeatures of the invention which are, for brevity, described in thecontext of a single embodiment, can also be provided separately or inany suitable subcombination.

As used herein, the phrase “optionally substituted” means unsubstitutedor substituted. As used herein, the term “substituted” means that ahydrogen atom is removed and replaced by a substituent. It is to beunderstood that substitution at a given atom is limited by valency.Throughout the definitions, the term “C_(i-j)” indicates a range whichincludes the endpoints, wherein i and j are integers and indicate thenumber of carbons. Examples include C₁₋₄, C₁₋₆, and the like.

The term “n-membered” where n is an integer typically describes thenumber of ring-forming atoms in a moiety where the number ofring-forming atoms is n. For example, piperidinyl is an example of a6-membered heterocycloalkyl ring, pyrazolyl is an example of a5-membered heteroaryl ring, pyridyl is an example of a 6-memberedheteroaryl ring, and 1, 2, 3, 4-tetrahydro-naphthalene is an example ofa 10-membered cycloalkyl group.

As used herein, the term “C_(i-j) alkyl,” employed alone or incombination with other terms, refers to a saturated hydrocarbon groupthat may be straight-chain or branched, having i to j carbons. In someembodiments, the alkyl group contains from 1 to 6 carbon atoms or from 1to 4 carbon atoms, or from 1 to 3 carbon atoms. Examples of alkylmoieties include, but are not limited to, chemical groups such asmethyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, and t-butyl.

As used herein, the term “C_(i-j) alkoxy,” employed alone or incombination with other terms, refers to a group of formula —O-alkyl,wherein the alkyl group has i to j carbons. Example alkoxy groupsinclude methoxy, ethoxy, and propoxy (e.g., n-propoxy and isopropoxy).In some embodiments, the alkyl group has 1 to 3 carbon atoms.

As used herein, “C_(i-j) alkenyl,” employed alone or in combination withother terms, refers to an unsaturated hydrocarbon group having one ormore double carbon-carbon bonds and having i to j carbons. In someembodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms.Example alkenyl groups include, but are not limited to, ethenyl,n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.

As used herein, “C_(i-j) alkynyl,” employed alone or in combination withother terms, refers to an unsaturated hydrocarbon group having one ormore triple carbon-carbon bonds and having i to j carbons. Examplealkynyl groups include, but are not limited to, ethynyl, propyn-1-yl,propyn-2-yl, and the like. In some embodiments, the alkynyl moietycontains 2 to 6 or 2 to 4 carbon atoms.

As used herein, the term “C_(i-j) alkylamino,” employed alone or incombination with other terms, refers to a group of formula —NH(alkyl),wherein the alkyl group has i to j carbon atoms. In some embodiments,the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “di-C_(i-j)-alkylamino,” employed alone or incombination with other terms, refers to a group of formula —N(alkyl)₂,wherein each of the two alkyl groups has, independently, i to j carbonatoms. In some embodiments, each alkyl group independently has 1 to 6 or1 to 4 carbon atoms.

As used herein, the term “C_(i-j) alkylthio,” employed alone or incombination with other terms, refers to a group of formula —S-alkyl,wherein the alkyl group has i to j carbon atoms. In some embodiments,the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “amino,” employed alone or in combination withother terms, refers to a group of formula —NH₂.

As used herein, the term “aryl,” employed alone or in combination withother terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or4 fused rings) aromatic hydrocarbon, such as, but not limited to,phenyl, 1-naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, and thelike. In some embodiments, aryl is C₆₋₁₀ aryl. In some embodiments, thearyl group is a naphthalene ring or phenyl ring. In some embodiments,the aryl group is phenyl.

As used herein, the term “carbonyl”, employed alone or in combinationwith other terms, refers to a —C(O)— group.

As used herein, the term “C_(i-j) cycloalkyl,” employed alone or incombination with other terms, refers to a non-aromatic cyclichydrocarbon moiety having i to j ring-forming carbon atoms, which mayoptionally contain one or more alkenylene groups as part of the ringstructure. Cycloalkyl groups can include mono- or polycyclic (e.g.,having 2, 3 or 4 fused rings) ring systems. Also included in thedefinition of cycloalkyl are moieties that have one or more aromaticrings fused (i.e., having a bond in common with) to the cycloalkyl ring,for example, benzo derivatives of cyclopentane, cyclopentene,cyclohexane, and the like. One or more ring-forming carbon atoms of acycloalkyl group can be oxidized to form carbonyl linkages. In someembodiments, cycloalkyl is C₃₋₇ cycloalkyl. Examplary cycloalkyl groupsinclude cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl,norbornyl, norpinyl, norcarnyl, and the like.

As used herein, “C_(i-j) haloalkoxy,” employed alone or in combinationwith other terms, refers to a group of formula —O-haloalkyl having i toj carbon atoms. An example haloalkoxy group is OCF₃. An additionalexample haloalkoxy group is OCHF₂. In some embodiments, the haloalkoxygroup is fluorinated only. In some embodiments, the alkyl group has 1 to6 or 1 to 4 carbon atoms.

As used herein, the term “halo,” employed alone or in combination withother terms, refers to a halogen atom selected from F, Cl, I or Br. Insome embodiments, “halo” refers to a halogen atom selected from F, Cl,or Br. In some embodiments, the halo substituent is F.

As used herein, the term “C_(i-j) haloalkyl,” employed alone or incombination with other terms, refers to an alkyl group having from onehalogen atom to 2s+1 halogen atoms which may be the same or different,where “s” is the number of carbon atoms in the alkyl group, wherein thealkyl group has i to j carbon atoms. In some embodiments, the haloalkylgroup is fluorinated only. In some embodiments, the haloalkyl group isfluoromethyl, difluoromethyl, or trifluoromethyl. In some embodiments,the haloalkyl group is trifluoromethyl. In some embodiments, the alkylgroup has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term “heteroaryl,” employed alone or in combinationwith other terms, refers to a monocyclic or polycyclic (e.g., having 2,3 or 4 fused rings) aromatic heterocylic moiety, having one or moreheteroatom ring members selected from nitrogen, sulfur and oxygen. Insome embodiments, the heteroaryl group has 1, 2, 3, or 4 heteroatom ringmembers. In some embodiments, the heteroaryl group has 1, 2, or 3heteroatom ring members. In some embodiments, the heteroaryl group has 1or 2 heteroatom ring members. In some embodiments, the heteroaryl grouphas 1 heteroatom ring member. In some embodiments, the heteroaryl groupis 5- to 10-membered. When the heteroaryl group contains more than oneheteroatom ring member, the heteroatoms may be the same or different.The nitrogen atoms in the ring(s) of the heteroaryl group can beoxidized to form N-oxides. Example heteroaryl groups include, but arenot limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole,pyrazole, azolyl, oxazole, isoxazole, thiazole, isothiazole, imidazole,furan, thiophene, triazole, tetrazole, thiadiazole, quinoline,isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole,imidazo[1, 2-b]thiazole, purine, triazine. and the like.

A 5-membered heteroaryl is a heteroaryl group having five ring-formingatoms comprising wherein one or more of the ring-forming atoms areindependently selected from N, O, and S. In some embodiments, the5-membered heteroaryl group has 1, 2, or 3 heteroatom ring members. Insome embodiments, the 5-membered heteroaryl group has 1 or 2 heteroatomring members. In some embodiments, the 5-membered heteroaryl group has 1heteroatom ring member. Example ring-forming members include CH, N, NH,O, and S. Example five-membered ring heteroaryls are thienyl, furyl,pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl,isoxazolyl, 1, 2, 3-triazolyl, tetrazolyl, 1, 2, 3-thiadiazolyl, 1, 2,3-oxadiazolyl, 1, 2, 4-triazolyl, 1, 2, 4-thiadiazolyl, 1, 2,4-oxadiazolyl, 1, 3, 4-triazolyl, 1, 3, 4-thiadiazolyl, and 1, 3,4-oxadiazolyl.

A 6-membered heteroaryl is a heteroaryl group having six ring-formingatoms wherein one or more of the ring-forming atoms is N. In someembodiments, the 6-membered heteroaryl group has 1, 2, or 3 heteroatomring members. In some embodiments, the 6-membered heteroaryl group has 1or 2 heteroatom ring members. In some embodiments, the 6-memberedheteroaryl group has 1 heteroatom ring member. Example ring-formingmembers include CH and N. Example six-membered ring heteroaryls arepyridyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl.

As used herein, the term “heterocycloalkyl,” employed alone or incombination with other terms, refers to non-aromatic heterocyclic ringsystem, which may optionally contain one or more unsaturations as partof the ring structure, and which has at least one heteroatom ring memberindependently selected from nitrogen, sulfur and oxygen. In someembodiments, the heterocycloalkyl group has 1, 2, 3, or 4 heteroatomring members. In some embodiments, the heterocycloalkyl group has 1, 2,or 3 heteroatom ring members. In some embodiments, the heterocycloalkylgroup has 1 or 2 heteroatom ring members. In some embodiments, theheterocycloalkyl group has 1 heteroatom ring member. When theheterocycloalkyl group contains more than one heteroatom in the ring,the heteroatoms may be the same or different. Example ring-formingmembers include CH, CH₂, C(O), N, NH, O, S, S(O), and S(O)₂.Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2,3 or 4 fused rings) ring systems, including spiro systems. Also includedin the definition of heterocycloalkyl are moieties that have one or morearomatic rings fused (i.e., having a bond in common with) to thenon-aromatic ring, for example, 1, 2, 3, 4-tetrahydro-quinoline,dihydrobenzofuran and the like. The carbon atoms or heteroatoms in thering(s) of the heterocycloalkyl group can be oxidized to form acarbonyl, sulfinyl, or sulfonyl group (or other oxidized linkage) or anitrogen atom can be quaternized. In some embodiments, heterocycloalkylis 5- to 10-membered. Examples of heterocycloalkyl groups include 1, 2,3, 4-tetrahydro-quinoline, dihydrobenzofuran, azetidine, azepane,pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, andpyran.

The compounds described herein can be asymmetric (e.g., having one ormore stereocenters). All stereoisomers, such as enantiomers anddiastereoisomers, are intended unless otherwise indicated. Compounds ofthe present invention that contain asymmetrically substituted carbonatoms can be isolated in optically active or racemic forms. Methods onhow to prepare optically active forms from optically inactive startingmaterials are known in the art, such as by resolution of racemicmixtures or by stereoselective synthesis. Many geometric isomers ofolefins, C═N double bonds, and the like can also be present in thecompounds described herein, and all such stable isomers are contemplatedin the present invention. Cis and trans geometric isomers of thecompounds of the present invention are described and may be isolated asa mixture of isomers or as separated isomeric forms.

When the compounds of the invention contain a chiral center, thecompounds can be any of the possible stereoisomers. In compounds with asingle chiral center, the stereochemistry of the chiral center can be(R) or (S). In compounds with two chiral centers, the stereochemistry ofthe chiral centers can each be independently (R) or (S) so theconfiguration of the chiral centers can be (R) and (R), (R) and (S); (S)and (R), or (S) and (S). In compounds with three chiral centers, thestereochemistry each of the three chiral centers can each beindependently (R) or (S) so the configuration of the chiral centers canbe (R), (R) and (R); (R), (R) and (S); (R), (S) and (R); (R), (S) and(S); (S), (R) and (R); (S), (R) and (S); (S), (S) and (R); or (S), (S)and (S).

Resolution of racemic mixtures of compounds can be carried out by any ofnumerous methods known in the art. An example method includes fractionalrecrystallization using a chiral resolving acid which is an opticallyactive, salt-forming organic acid. Suitable resolving agents forfractional recrystallization methods are, for example, optically activeacids, such as the D and L forms of tartaric acid, diacetyltartaricacid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid orthe various optically active camphorsulfonic acids such asβ-camphorsulfonic acid. Other resolving agents suitable for fractionalcrystallization methods include stereoisomerically pure forms ofα-methylbenzylamine (e.g., S and R forms, or diastereoisomerically pureforms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine,cyclohexylethylamine, 1, 2-diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on acolumn packed with an optically active resolving agent (e.g.,dinitrobenzoylphenylglycine). Suitable elution solvent composition canbe determined by one skilled in the art.

Compounds of the invention also include tautomeric forms. Tautomericforms result from the swapping of a single bond with an adjacent doublebond together with the concomitant migration of a proton. Tautomericforms include prototropic tautomers which are isomeric protonationstates having the same empirical formula and total charge. Exampleprototropic tautomers include ketone-enol pairs, amide-imidic acidpairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-iminepairs, and annular forms where a proton can occupy two or more positionsof a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H-and 4H-1, 2, 4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole.Tautomeric forms can be in equilibrium or sterically locked into oneform by appropriate substitution.

Compounds of the invention can also include all isotopes of atomsoccurring in the intermediates or final compounds. Isotopes includethose atoms having the same atomic number but different mass numbers.

The term “compound” as used herein is meant to include allstereoisomers, geometric isomers, tautomers, and isotopes of thestructures depicted. Compounds herein identified by name or structure asone particular tautomeric form are intended to include other tautomericforms unless otherwise specified (e.g., in the case of purine rings,unless otherwise indicated, when the compound name or structure has the9H tautomer, it is understood that the 7H tautomer is also encompassed).

All compounds, and pharmaceutically acceptable salts thereof, can befound together with other substances such as water and solvents (e.g.,hydrates and solvates) or can be isolated.

In some embodiments, the compounds of the invention, or salts thereof,are substantially isolated. By “substantially isolated” is meant thatthe compound is at least partially or substantially separated from theenvironment in which it was formed or detected. Partial separation caninclude, for example, a composition enriched in a compound of theinvention. Substantial separation can include compositions containing atleast about 50%, at least about 60%, at least about 70%, at least about80%, at least about 90%, at least about 95%, at least about 97%, or atleast about 99% by weight of the compounds of the invention, or saltthereof. Methods for isolating compounds and their salts are routine inthe art.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The expressions, “ambient temperature” and “room temperature,” as usedherein, are understood in the art, and refer generally to a temperature,e.g., a reaction temperature, that is about the temperature of the roomin which the reaction is carried out, for example, a temperature fromabout 20° C. to about 30° C.

The present invention also includes pharmaceutically acceptable salts ofthe compounds described herein. As used herein, “pharmaceuticallyacceptable salts” refers to derivatives of the disclosed compoundswherein the parent compound is modified by converting an existing acidor base moiety to its salt form. Examples of pharmaceutically acceptablesalts include, but are not limited to, mineral or organic acid salts ofbasic residues such as amines; alkali or organic salts of acidicresidues such as carboxylic acids; and the like. The pharmaceuticallyacceptable salts of the present invention include the conventionalnon-toxic salts of the parent compound formed, for example, fromnon-toxic inorganic or organic acids. The pharmaceutically acceptablesalts of the present invention can be synthesized from the parentcompound which contains a basic or acidic moiety by conventionalchemical methods. Generally, such salts can be prepared by reacting thefree acid or base forms of these compounds with a stoichiometric amountof the appropriate base or acid in water or in an organic solvent, or ina mixture of the two; generally, non-aqueous media like ether, ethylacetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) oracetonitrile (MeCN) are preferred. Lists of suitable salts are found inRemington's Pharmaceutical Sciences, 17^(th) Ed., (Mack PublishingCompany, Easton, 1985), p. 1418, Berge et al., J. Pharm. Sci., 1977,66(1), 1-19, and in Stahl et al., Handbook of Pharmaceutical Salts:Properties, Selection, and Use, (Wiley, 2002). In some embodiments, thecompounds described herein include the N-oxide forms.

The following abbreviations may be used herein: AcOH (acetic acid); Ac₂O(acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc(t-butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc. (calculated);d (doublet); dd (doublet of doublets); DCM (dichloromethane); DIAD (N,N′-diisopropyl azidodicarboxylate); DIPEA (N, N-diisopropylethylamine);DMF (N, N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g(gram(s)); h (hour(s)); HATU (N, N, N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate);HCl (hydrochloric acid); HPLC (high performance liquid chromatography);Hz (hertz); J (coupling constant); LCMS (liquid chromatography-massspectrometry); m (multiplet); M (molar); mCPBA (3-chloroperoxybenzoicacid); MgSO₄ (magnesium sulfate); MS (Mass spectrometry); Me (methyl);MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min.(minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal);NaHCO₃ (sodium bicarbonate); NaOH (sodium hydroxide); Na₂SO₄ (sodiumsulfate); NH₄Cl (ammonium chloride); NH₄OH (ammonium hydroxide); nM(nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf(trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); pM(picomolar); POCl₃ (phosphoryl chloride); RP-HPLC (reverse phase highperformance liquid chromatography); s (singlet); t (triplet ortertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (tripletof triplets); t-Bu (tert-butyl); TFA (trifluoroacetic acid); THF(tetrahydrofuran); μg (microgram(s)); μL (microliter(s)); μM(micromolar); wt % (weight percent).

Synthesis

Compounds of the invention, including salts thereof, can be preparedusing known organic synthesis techniques and can be synthesizedaccording to any of numerous possible synthetic routes.

The reactions for preparing compounds of the invention can be carriedout in suitable solvents which can be readily selected by one of skillin the art of organic synthesis. Suitable solvents can be substantiallynon-reactive with the starting materials (reactants), the intermediates,or products at the temperatures at which the reactions are carried out,e.g., temperatures which can range from the solvent's freezingtemperature to the solvent's boiling temperature. A given reaction canbe carried out in one solvent or a mixture of more than one solvent.Depending on the particular reaction step, suitable solvents for aparticular reaction step can be selected by the skilled artisan.

Preparation of compounds of the invention can involve the protection anddeprotection of various chemical groups. The need for protection anddeprotection, and the selection of appropriate protecting groups, can bereadily determined by one skilled in the art. The chemistry ofprotecting groups can be found, for example, in P. G. M. Wuts and T. W.Greene, Protective Groups in Organic Synthesis, 4^(th) Ed., Wiley &Sons, Inc., New York (2006), which is incorporated herein by referencein its entirety. Protecting groups in the synthetic schemes aretypically represented by “PG.”

Reactions can be monitored according to any suitable method known in theart. For example, product formation can be monitored by spectroscopicmeans, such as nuclear magnetic resonance spectroscopy (e.g., ¹H or¹³C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), massspectrometry, or by chromatographic methods such as high performanceliquid chromatography (HPLC), liquid chromatography-mass spectroscopy(LCMS), or thin layer chromatography (TLC). Compounds can be purified bythose skilled in the art by a variety of methods, including highperformance liquid chromatography (HPLC) (“Preparative LC-MSPurification: Improved Compound Specific Method Optimization” Karl F.Blom, Brian Glass, Richard Sparks, Andrew P. Combs J. Combi. Chem. 2004,6(6), 874-883, which is incorporated herein by reference in itsentirety) and normal phase silica chromatography.

Compounds of Formula I can be formed as shown in Scheme I. Theheterocyclic halide (i) (Hal=Cl, Br, or I) can be coupled to M-Het,where M is a boronic acid, boronic ester or an appropriately substitutedmetal (e.g., Het-M is Het-B(OH)₂, Het-Sn(Bu)₄, or Zn-Het), understandard Suzuki conditions or standard Stille conditions (e.g., in thepresence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) and a base (e.g., bicarbonateor carbonate base) or standard Negishi conditions (e.g., in the presenceof a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)), to give a derivative ofFormula I (iii).

Alternatively, heterocyclic halide (i) can be converted to a boronicacid or boronate ester (iv) under standard transmetalation conditions(e.g., pinacol boronate, in the presence of a palladium(0) catalyst,such as tetrakis(triphenylphosphine)palladium(0)). The heterocyclicboronate (iv) can be coupled to halo substituted heterocycles (v),(e.g., Hal-Het, where Hal=Cl, Br, or I), under standard Suzukiconditions or standard Stille conditions (e.g., in the presence of apalladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0))and a base (e.g., bicarbonate or carbonate base) or standard Negishiconditions (e.g., in the presence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give a compound of FormulaI (iii).

Synthesis of heterocyclic intermediates useful in the preparation ofcompounds of Formula I can be formed as shown in Scheme II. Theheterocycle (i) can be alkylated (e.g., Z-Hal, where Hal=Br, Cl, or I)with a base (e.g., triethylamine, NaH or Na₂CO₃) or under Mitsunobuconditions to afford the heterocycle (ii). Alternatively, heterocycle(i) can be arylated either under Evans' conditions with an aryl-boronicacid (e.g., Z—B(OR)₂, in the presence of a palladium(0) catalyst) orUllman conditions with an aryl halide (e.g., Z-Hal, in the presence ofpalladium(0)) to afford the heterocycle (ii). Halogenation ofheterocycle (ii) under standard conditions (Br₂, AcOH orN-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can givehalide (iii) where Hal=Cl, Br or I.

Synthesis of heterocyclic intermediates useful in the preparation ofcompounds of Formula I can be formed as shown in Scheme III.Halogenation of heterocycle (i) under standard conditions (e.g., Br₂,AcOH or N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide)can give halide (ii) where Hal=Cl, Br or I. The heterocycle (ii) can bealkylated (e.g., Z-Hal, where Hal=Br, Cl, or I) with a base, (e.g.triethylamine, NaH or Na₂CO₃) or under Mitsunobu conditions to affordthe heterocycle (iii). Alternatively, heterocycle (ii) can be arylatedeither under Evans' conditions with an aryl-boronic acid (e.g.,Z—B(OR)₂, in the presence of a palladium(0) catalyst) or Ullmannconditions with an aryl halide (e.g., Z-Hal, in the presence of copper)to afford the heterocycle (iii).

Compounds of Formula I can be formed as shown in Scheme IV. Theheterocyclic fluoride (i) can be coupled to Het-M (ii), where M is aboronic acid, boronic ester or an appropriately substituted metal (e.g.,Het-M is Het-B(OH)₂, Het-B(OR)₂, Het-Sn(Bu)₄, or Zn-Het), under standardSuzuki conditions or standard Stille conditions (e.g., in the presenceof a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonateor carbonate base)) or standard Negishi conditions (e.g., in thepresence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)), to give a compound of formula(iii).

Alternatively, heterocyclic halide (i) can be converted to a boronicacid or boronate acid (iv) under standard transmetalation conditions(e.g., pinacol boronate, in the presence of a palladium(0) catalyst,such as tetrakis(triphenylphosphine)palladium(0)). The heterocyclicboronate (iv) can be coupled to halo substituted heterocycle (v) (e.g.,Hal-Het, where Hal is a halide (e.g., Hal=Cl, Br, or I)), under standardSuzuki conditions or standard Stille conditions (e.g., in the presenceof a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonateor carbonate base)) or standard Negishi conditions (e.g., in thepresence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give the compounds offormula (iii). Thiols, amines, and alcohols of formula H-L-Z candisplace the fluoro group of compounds (iii) using standard conditions(e.g., Cs₂CO₃/DMSO) to give thioethers, arylamines, and ethers ofFormula I (vi) after deprotection of the nitrogen protecting group andoptional alkylation with Hal-R².

Synthesis of heterocyclic intermediates useful in the preparation ofcompounds of Formula I can be formed as shown in Scheme V. Conversion ofHal derivative (i) wherein Hal=Br, Cl, or I, with1,1-dimethoxy-N,N-dimethylmethanamine in the absence or presence of abase can provide enamines (ii). Catalytic hydrogenation of (ii) in thepresence of a catalyst (e.g., Raney-Nickel under hydrogen atmosphere)can provide amines that cyclize to form a heterocycle. Protection of theheterocyclic nitrogen atom with a protecting group such as, but notlimited to, benzyl, tosyl, and (trimethylsilyl)ethoxy)methyl group canprovide heterocycle (iii). Hydrolysis of the methoxy substituent with anacid such as, but not limited to, hydrochloric acid or hydrobromic acidprovides heterocycles (iv). Compound (iv) can be alkylated (e.g., R²-Haland a base (e.g., triethylamine, NaH or Na₂CO₃) or under Mitsunobuconditions) to afford the heterocycle (v). The conversion of halide (v)to the boronate ester (vi) or boronic acid (vi) can be performed understandard conditions (e.g., pinacol boronate, in the presence of apalladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)).

Synthesis of heterocyclic intermediates useful in the preparation ofcompounds of Formula I can be formed as shown in Scheme VI. Conversionof halo heterocycle (i) with ammonium hydroxide can afford amines (ii).Iodination of amine (ii) with N-iodosuccinimide can afford iododerivatives (iii). Coupling with(E)-2-(2-ethoxyvinyl)-4,4,S,S-tetramethyl-1,3,2-dioxaborolane utilizingSuzuki coupling reaction conditions (e.g., in the presence of apalladium(0) catalyst, such as tetrakis(triphenylphosphine)palladium(0)and a base (e.g., bicarbonate or carbonate base)) can provideheterocycles (iv). Cyclization of (iv) in the presence of an acid suchas, but not limited to, acetic acid or hydrochloric acid, followed byprotection of the nitrogen atom can afford heterocycles (v). Theconversion of halide (v) to the boronate ester (vi) or boronic acid (vi)can be performed under standard conditions (e.g., pinacol boronate, inthe presence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)).

Synthesis of heterocyclic intermediates useful in the preparation ofcompounds of Formula I can be formed as shown in Scheme VII. Conversionof iodo derivative (i) to heterocyclic acid (ii) can be performed byreacting with pyruvic acid in the presence of a palladium catalyst(e.g., palladium(II)acetate, and a base such as DBU). Esterification ofthe acid (ii) can be performed by standard reaction conditions such astreatment with an alcohol under acidic condition. Protection of thenitrogen of the heterocycle (iii) can be performed under standardconditions to give N-protected heterocycle (iv). Hydrolysis of the esterto the acid and formation of the amide (v) can be performed understandard peptide coupling conditions, (e.g., amine HNRR in the presenceof a coupling reagent, such as, 1,1′-carbonyldiimidazole (CDI) orN,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU)). The conversionof halide (v) to the boronate ester (vi) or boronic acid (vi) can beperformed under standard condition (e.g., pinacol boronate, in thepresence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)).

Synthesis of heterocyclic intermediates useful in the preparation ofcompounds of Formula I can be formed as shown in Scheme VIII. Reactionof heterocycle (i) with an oxalate ester in the presence of a base(e.g., potassium ethoxide) and reduction followed by cyclization of theresulting ester (ii) upon heating and protection of the heterocyclicnitrogen can afford heterocycle (iii). Cleavage of the methyl etherunder acidic conditions can afford heterocycle (iv). Compounds offormula (iv) can be alkylated (e.g., R²-Hal, where Hal=Br, Cl, or I)with a base, such as triethylamine, NaH or Na₂CO₃ or under Mitsunobuconditions to afford the heterocycle (v). The conversion of halide (v)to the boronate ester (vi) or boronic acid (vi) can be performed understandard condition (e.g., pinacol boronate, in the presence of apalladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)).

Synthesis of heterocyclic intermediates useful in the preparation ofcompounds of Formula I can be formed as shown in Scheme IX. Heterocycle(i) can be alkylated with R²-Hal (Hal=Cl, Br, I, or other leaving group,e.g., MeI) and a suitable base (e.g., NaH) to give compound (ii).Selective reduction of the nitro heterocycle (ii) (e.g., Hal=Cl, Br or Iusing iron with AcOH or HCl) can give the amine (iii). Cyclization of(iii) to (iv) can be accomplished by isoamylnitrite. Protection of thenitrogen of (iv) can be accomplished using standard conditions (e.g.,tosylchloride and NaH) to give (v). The conversion of halide (v) to theboronate ester (vi) or boronic acid (vi) can be performed under standardcondition (e.g., pinacol boronate, in the presence of a palladium(0)catalyst, such as tetrakis(triphenylphosphine)palladium(0)).

Synthesis of compounds of Formula I can be formed as shown in Scheme X.Thiols, amines, and alcohols of formula H-L-Z can displace the fluorogroup of compounds (i) using standard conditions (e.g., Cs₂CO₃/DMSO) togive thioethers, arylamines, and ethers of formula (ii) where L=S, NR,and O, respectively. Selective reduction of the nitro benzene (ii) (whenHal=Cl, Br or I) using iron/AcOH can give the bis-aniline (iii).Conversion of bis-aniline to urea can occur under standard conditions(e.g., carbonyl diimidazole or triphosgene) to give (iv). Theheterocyclic halide (iv) can be coupled to Het-M (v), where M is aboronic acid, boronic ester or an appropriately substituted metal (e.g.,Het-M is Het-B(OH)₂, Het-B(OR)₂, Het-Sn(Bu)₄, or Zn-Het), under standardSuzuki conditions or standard Stille conditions (e.g., in the presenceof a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) and a base (e.g., bicarbonateor carbonate base) or standard Negishi conditions (e.g., in the presenceof a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give compounds (vi).Deprotection of (vi) can give compounds of Formula I (vii).

Compounds of Formula I can be formed as shown in Scheme XI. Aniline (i)(from Scheme X) can be converted to the trifluoroacetamide usingstandard conditions (e.g., trifluoroacetic anhydride) and then alkylatedwith R^(B)-Hal (e.g., Hal=Cl, Br, I, or other leaving group, e.g., MeI)and a suitable base (e.g., NaH) to give compound (ii). Removal of thetrifluoroacetamide followed by selective reduction of the nitro (whenHal=Cl, Br or I) using iron/AcOH can give the bis-aniline (iii).Conversion of bis-aniline to urea can occur under standard conditions(e.g., carbonyl diimidazole or triphosgene) to give (iv). Theheterocyclic halide (iv) can be coupled to Het-M (v), where M is aboronic acid, boronic ester or an appropriately substituted metal (e.g.,Het-M is Het-B(OH)₂, Het-B(OR)₂, Het-Sn(Bu)₄, or Zn-Het), under standardSuzuki conditions or standard Stille conditions (e.g., in the presenceof a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonateor carbonate base)) or standard Negishi conditions (e.g., in thepresence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give compounds (vi).Deprotection of (vi) can give compounds of the invention (vii).

Compounds of Formula I can be formed as shown in Scheme XII. The aniline(i) can be coupled to Het-M (ii), where M is a boronic acid, boronicester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)₂,Het-B(OR)₂, Het-Sn(Bu)₄, or Zn-Het), under standard Suzuki conditions orstandard Stille conditions (e.g., in the presence of a palladium(0)catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base(e.g., bicarbonate or carbonate base)) or standard Negishi conditions(e.g., in the presence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give compounds (iii). Thenitro group of (iii) can be reduced to give the bis-aniline which can beconverted to the urea under standard conditions (e.g., carbonyldiimidazole or triphosgene) to give (vii). Deprotection of (vii) cangive compounds of the invention (vi).

Alternatively, the aniline of compound (iii) can be converted to thetrifluoroacetamide using standard conditions (e.g., trifluoroaceticanhydride) and then alkylated with R^(B)-Hal (Hal=Cl, Br, I, or otherleaving group, eg. MeI) and a suitable base (e.g., NaH) to give compound(iv). Removal of the trifluoroacetamide followed by reduction of thenitro under standard conditions (e.g., hydrogenation with palladium,iron/AcOH, or zinc) can give the bis-aniline which can be converted tothe urea under standard conditions (e.g., carbonyl diimidazole ortriphosgene) to give (v). Finally deprotection of (v) can give compoundsof the invention (vi).

Compounds of Formula I can be formed as shown in Scheme XIII. Selectivereduction of the nitro benzene (i) (when Hal=Cl, Br or I) usingiron/AcOH can give the bis-aniline which can be converted under standardconditions (e.g., (EtO)₃CR^(B) with p-TsOH, R^(B)CHO with TMSCl orperoxide/HCL or copper catalyzed, or R^(B)CO₂H with borane) to givebenzimidazole (ii). The benzimidazole (ii) can be coupled to Het-M(iii), where M is a boronic acid, boronate ester or an appropriatelysubstituted metal (e.g., Het-M is Het-B(OH)₂, Het-B(OR)₂, Het-Sn(Bu)₄,or Zn-Het), under standard Suzuki conditions or standard Stilleconditions (e.g., in the presence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonateor carbonate base)) or standard Negishi conditions (e.g., in thepresence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give compounds (iv).Finally deprotection of (iv) can give compounds of the invention (v).

Alternatively, aniline (i) can be converted to the trifluoroacetamideusing standard conditions (e.g., trifluoroacetic anhydride) and thenalkylated with R^(B)-Hal (Hal=Cl, Br, I, or other leaving group, eg.MeI) and a suitable base (e.g., NaH) to give compound (vi). Removal ofthe trifluoroacetamide followed by selective reduction of the nitro(when Hal=Cl, Br or I) using iron/AcOH can give the bis-aniline whichcan be converted under standard conditions (e.g., (EtO)₃CR^(B) withp-TsOH, R^(B)CHO with TMSCl or peroxide/HCL or copper catalyzed, orR^(B)CO₂H with borane) to give benzimidazole (vii). The benzimidazole(vii) can be coupled to Het-M (iii), where M is a boronic acid, boronicester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)₂,Het-B(OR)₂, Het-Sn(Bu)₄, or Zn-Het), under standard Suzuki conditions orstandard Stille conditions (e.g., in the presence of a palladium(0)catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base(e.g., bicarbonate or carbonate base)) or standard Negishi conditions(e.g., in the presence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give compounds of theinvention (v) after deprotection and optional alkylation.

Compounds of Formula I can be formed as shown in Scheme XIV. Selectivereduction of the nitro benzene (i) (when Hal=Cl, Br or I) usingiron/AcOH can give the bis-aniline which can be converted (e.g., sodiumnitrite/acetic acid) to benzotriazole (ii). The benzotriazole (ii) canbe coupled to Het-M (iii), where M is a boronic acid, boronate ester oran appropriately substituted metal (e.g., Het-M is Het-B(OH)₂,Het-B(OR)₂, Het-Sn(Bu)₄, or Zn-Het), under standard Suzuki conditions orstandard Stille conditions (e.g., in the presence of a palladium(0)catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base(e.g., bicarbonate or carbonate base)) or standard Negishi conditions(e.g., in the presence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give compounds (iv).Finally deprotection of (iv) can give compounds of the invention (v).

Alternatively, aniline (i) can be converted to the trifluoroacetamideusing standard conditions (e.g., trifluoroacetic anhydride) and thenalkylated with R^(B)-Hal (Hal=Cl, Br, I, or other leaving group, eg.MeI) and a suitable base (e.g., NaH) to give compound (vi). Removal ofthe trifluoroacetamide followed by selective reduction of the nitro(when Hal=Cl, Br or I) using iron/AcOH can give the bis-aniline whichcan be converted (e.g., sodium nitrite with acetic acid) tobenzotriazole (vii). The benzotriazole (vii) can be coupled to Het-M(iii), where M is a boronic acid, boronic ester or an appropriatelysubstituted metal (e.g., Het-M is Het-B(OH)₂, Het-B(OR)₂, Het-Sn(Bu)₄,or Zn-Het), under standard Suzuki conditions or standard Stilleconditions (e.g., in the presence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonateor carbonate base)) or standard Negishi conditions (e.g., in thepresence of a palladium(0) catalyst, such astetrakis(triphenylphosphine)palladium(0)) to give compounds of theinvention (v) after deprotection and optional alkylation.

Methods of Use

Compounds of the invention are BET protein inhibitors and, thus, areuseful in treating diseases and disorders associated with activity ofBET proteins. For the uses described herein, any of the compounds of theinvention, including any of the embodiments thereof, may be used.

The compounds of the invention can inhibit one or more of BET proteinsBRD2, BRD3, BRD4, and BRD-t. In some embodiments, the BET protein isBRD2. In some embodiments, the BET protein is BRD3. In some embodiments,the BET protein is BRD4. In some embodiments, the BET protein is BRD-t.In some embodiments, the compounds of the invention selectively inhibitone or more BET proteins over another. “Selective” means that thecompound binds to or inhibits a BET protein with greater affinity orpotency, respectively, compared to a reference, such as another BETprotein. For example, the compounds can be selective for BRD2 over BRD3,BRD4 and BRD-t, selective for BRD3 over BRD2, BRD4 and BRD-t, selectivefor BRD4 over BRD2, BRD3 and BRD-t, or selective for BRD-t over BRD2,BRD3 and BRD4. In some embodiments, the compounds inhibit two or more ofthe BET proteins, or all of the BET proteins. In general, selectivitycan be at least about 5-fold, at least about 10-fold, at least about20-fold, at least about 50-fold, at least about 100-fold, at least about200-fold, at least about 500-fold or at least about 1000-fold.

In some embodiments, the present invention is directed to a method ofinhibiting BRD2 comprising contacting a compound of the invention withBRD2. In some embodiments, the present invention is directed to a methodof inhibiting BRD3 comprising contacting a compound of the inventionwith BRD3. In some embodiments, the present invention is directed to amethod of inhibiting BRD4 comprising contacting a compound of theinvention with BRD4. In some embodiments, the present invention isdirected to a method of inhibiting BRD-t comprising contacting acompound of the invention with BRD-t.

The compounds of the invention are therefore useful for treating BETprotein mediated disorders. The term “BET-mediated” refers to anydisease or condition in which one or more of the BET proteins, such asBRD2, BRD3, BRD4 and/or BRD-t, or a mutant thereof, plays a role, orwhere the disease or condition is associated with expression or activityof one or more of the BET proteins. The compounds of the invention cantherefore be used to treat or lessen the severity of diseases andconditions where BET proteins, such as BRD2, BRD3, BRD4, and/or BRD-t,or a mutant thereof, are known to play a role.

Diseases and conditions treatable using the compounds of the inventioninclude, but are not limited to, cancer and other proliferativedisorders, autoimmune disease, chronic inflammatory diseases, acuteinflammatory diseases, sepsis, and viral infection. The diseases can betreated by administering to an individual (e.g., a patient) in need ofthe treatment a therapeutically effective amount or dose of a compoundof the invention, or any of the embodiments thereof, or a pharmaceuticalcomposition thereof. The present disclosure also provides a compound ofthe invention, or any of the embodiments thereof, or a pharmaceuticalcomposition thereof, for use in treating a BET-mediated disease ordisorder. Also provided is the use of a compound of the invention, orany of the embodiments thereof, or a pharmaceutical composition thereof,in the manufacture of a medicament for treating a BET-mediated diseaseor disorder.

Diseases that can be treated with the compounds of the invention includecancers. The cancers can include, but are not limited to, adrenalcancer, acinic cell carcinoma, acoustic neuroma, acral lentiginousmelanoma, acrospiroma, acute eosinophilic leukemia, acute erythroidleukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia,acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma,adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor,adenosquamous carcinoma, adipose tissue neoplasm, adrenocorticalcarcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia,AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft partsarcoma, ameloblastic fibroma, anaplastic large cell lymphoma,anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma,angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoidtumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocyticleukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer,bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor,Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma insitu, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma,chondroma, chordoma, choriocarcinoma, choroid plexus papilloma,clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-celllymphoma, cervical cancer, colorectal cancer, Degos disease,desmoplastic small round cell tumor, diffuse large B-cell lymphoma,dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonalcarcinoma, endocrine gland neoplasm, endodermal sinus tumor,enteropathy-associated T-cell lymphoma, esophageal cancer, fetus infetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroidcancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor,gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumorof the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosiscerebri, glucagonoma, gonadoblastoma, granulosa cell tumor,gynandroblastoma, gallbladder cancer, gastric cancer, hairy cellleukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma,hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma,Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma,intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna,lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lungcancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma,acute lymphocytic leukemia, acute myelogenous leukemia, chroniclymphocytic leukemia, liver cancer, small cell lung cancer, non-smallcell lung cancer, MALT lymphoma, malignant fibrous histiocytoma,malignant peripheral nerve sheath tumor, malignant triton tumor, mantlecell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia,mediastinal germ cell tumor, medullary carcinoma of the breast,medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkelcell cancer, mesothelioma, metastatic urothelial carcinoma, mixedMullerian tumor, mucinous tumor, multiple myeloma, muscle tissueneoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma,nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma,neuroma, nodular melanoma, ocular cancer, oligoastrocytoma,oligodendroglioma, oncocytoma, optic nerve sheath meningioma, opticnerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor,papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma,pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma,polyembryoma, precursor T-lymphoblastic lymphoma, primary centralnervous system lymphoma, primary effusion lymphoma, primary peritonealcancer, prostate cancer, pancreatic cancer, pharyngeal cancer,pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma,retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation,rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor,sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer,small blue round cell tumors, small cell carcinoma, soft tissue sarcoma,somatostatinoma, soot wart, spinal tumor, splenic marginal zonelymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease,small intestine cancer, squamous carcinoma, stomach cancer, T-celllymphoma, testicular cancer, thecoma, thyroid cancer, transitional cellcarcinoma, throat cancer, urachal cancer, urogenital cancer, urothelialcarcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visualpathway glioma, vulvar cancer, vaginal cancer, Waldenstrom'smacroglobulinemia, Warthin's tumor, and Wilms' tumor. In someembodiments, the cancer can be adenocarcinoma, adult T-cellleukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast cancer,brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectalcancer, esophageal cancer, gastrointestinal cancer, glioblastomamultiforme, glioma, gallbladder cancer, gastric cancer, head and neckcancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer,kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, livercancer, small cell lung cancer, non-small cell lung cancer,mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oralcancer, ovarian cancer, pituitary tumor, primary central nervous systemlymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renalcell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, smallintestine cancer, stomach cancer, T-cell lymphoma, testicular cancer,thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma,uterine cancer, vaginal cancer, or Wilms' tumor.

The diseases treatable using the compounds of the invention also includeMYC dependent cancers wherein the cancer is associated with at least oneof myc RNA expression or MYC protein expression. A patient can beidentified for such treatment by determining myc RNA expression or MYCprotein expression in the cancerous tissue or cells.

Diseases that can be treated with compounds of the invention alsoinclude non-cancerous proliferative disorders. Examples of proliferativedisorders that can be treated include, but are not limited to, benignsoft tissue tumors, bone tumors, brain and spinal tumors, eyelid andorbital tumors, granuloma, lipoma, meningioma, multiple endocrineneoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumorcerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cysticneoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, andcysts, Castleman disease, chronic pilonidal disease, dermatofibroma,pilar cyst, pyogenic granuloma, and juvenile polyposis syndrome.

The diseases and conditions that can be treated with the compounds ofthe invention also include chronic autoimmune and inflammatoryconditions. Examples of autoimmune and inflammatory conditions that canbe treated include acute, hyperacute or chronic rejection oftransplanted organs, acute gout, acute inflammatory responses (such asacute respiratory distress syndrome and ischemia/reperfusion injury),Addison's disease, agammaglobulinemia, allergic rhinitis, allergy,alopecia, Alzheimer's disease, appendicitis, atherosclerosis, asthma,osteoarthritis, juvenile arthritis, psoriatic arthritis, rheumatoidarthriti, satopic dermatitis, autoimmune alopecia, autoimmune hemolyticand thrombocytopenic states, autoimmune hypopituitarism, autoimmunepolyglandular disease, Behcet's disease, bullous skin diseases,cholecystitis, chronic idiopathic thrombocytopenic purpura, chronicobstructive pulmonary disease (COPD), cirrhosis, degenerative jointdisease, depression, dermatitis, dermatomyositis, eczema, enteritis,encephalitis, gastritis glomerulonephritis, giant cell arteritis,Goodpasture's syndrome, Guillain-Barre syndrome, gingivitis, Graves'disease, Hashimoto's thyroiditis, hepatitis, hypophysitis, inflammatorybowel disease (Crohn's disease and ulcerative colitis), inflammatorypelvic disease, irritable bowel syndrome, Kawasaki disease, LPS-inducedendotoxic shock, meningitis, multiple sclerosis, myocarditis, myastheniagravis, mycosis fungoides, myositis, nephritis, osteomyelitis,pancreatitis, Parkinson's disease, pericarditis, pernicious anemia,pneumonitis, primary biliary sclerosing cholangitis, polyarteritisnodosa, psoriasis, retinitis, scleritis, scleracierma, scleroderma,sinusitis, Sjogren's disease, sepsis, septic shock, sunburn, systemiclupus erythematosus, tissue graft rejection, thyroiditis, type Idiabetes, Takayasu's arteritis, urethritis, uveitis, vasculitis,vasculitis including giant cell arteritis, vasculitis with organinvolvement such as glomerulonephritis, vitiligo, Waldenstrommacroglobulinemia and Wegener's granulomatosis.

The diseases and conditions that can be treated with the compounds ofthe invention also include diseases and conditions which involveinflammatory responses to infections with bacteria, viruses, fungi,parasites or their toxins, such as sepsis, sepsis syndrome, septicshock, endotoxaemia, systemic inflammatory response syndrome (SIRS),multi-organ dysfunction syndrome, toxic shock syndrome, acute lunginjury, ARDS (adult respiratory distress syndrome), acute renal failure,fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes,sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis,malaria, SIRS associated with viral infections such as influenza, herpeszoster, herpes simplex and coronavirus.

Other diseases that can be treated with the compounds of the inventioninclude viral infections. Examples of viral infections that can betreated include Epstein-Barr virus, hepatitis B virus, hepatitis Cvirus, herpes virus, human immunodeficiency virus, human papillomavirus, adenovirus, poxvirus and other episome-based DNA viruses. Thecompounds can therefore be used to treat disease and conditions such asherpes simplex infections and reactivations, cold sores, herpes zosterinfections and reactivations, chickenpox, shingles, human papillomavirus, cervical neoplasia, adenovirus infections, including acuterespiratory disease, and poxvirus infections such as cowpox and smallpoxand African swine fever virus. In one particular embodiment, thecompounds of the invention are indicated for the treatment of humanpapilloma virus infections of skin or cervical epithelia.

The diseases and conditions that can be treated with the compounds ofthe invention also include conditions that are associated withischaemia-reperfusion injury. Examples of such conditions include, butare not limited to conditions such as myocardial infarction,cerebrovascular ischaemia (stroke), acute coronary syndromes, renalreperfusion injury, organ transplantation, coronary artery bypassgrafting, cardio-pulmonary bypass procedures and pulmonary, renal,hepatic, gastro-intestinal or peripheral limb embolism.

The compounds of the invention are also useful in the treatment ofdisorders of lipid metabolism via the regulation of APO-A1 such ashypercholesterolemia, atherosclerosis and Alzheimer's disease.

The compounds of the invention are also useful in the treatment offibrotic conditions such as idiopathic pulmonary fibrosis, renalfibrosis, post-operative stricture, keloid formation, scleroderma andcardiac fibrosis.

The compounds of the invention can also be used to treat ophthamologicalindications such as dry eye.

The compounds of the invention can also be used to treat heart diseasesuch as heart failure.

As used herein, the term “contacting” refers to the bringing together ofindicated moieties in an in vitro system or an in vivo system. Forexample, “contacting” a BET protein with a compound of the inventionincludes the administration of a compound of the present invention to anindividual or patient, such as a human, having a BET protein, as wellas, for example, introducing a compound of the invention into a samplecontaining a cellular or purified preparation containing the BETprotein.

As used herein, the term “individual” or “patient,” usedinterchangeably, refers to any animal, including mammals, preferablymice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep,horses, or primates, and most preferably humans.

As used herein, the phrase “therapeutically effective amount” refers tothe amount of active compound or pharmaceutical agent that elicits thebiological or medicinal response that is being sought in a tissue,system, animal, individual or human by a researcher, veterinarian,medical doctor or other clinician.

As used herein, the term “treating” or “treatment” refers to inhibitingthe disease; for example, inhibiting a disease, condition or disorder inan individual who is experiencing or displaying the pathology orsymptomatology of the disease, condition or disorder (i.e., arrestingfurther development of the pathology and/or symptomatology) orameliorating the disease; for example, ameliorating a disease, conditionor disorder in an individual who is experiencing or displaying thepathology or symptomatology of the disease, condition or disorder (i.e.,reversing the pathology and/or symptomatology) such as decreasing theseverity of disease.

As used herein, the term “preventing” or “prevention” refers topreventing the disease; for example, preventing a disease, condition ordisorder in an individual who may be predisposed to the disease,condition or disorder but does not yet experience or display thepathology or symptomatology of the disease.

Combination Therapies

The compounds of the invention can be used in combination treatmentswhere the compound of the invention is administered in conjunction withother treatments such as the administration of one or more additionaltherapeutic agents. The additional therapeutic agents are typicallythose which are normally used to treat the particular condition to betreated. The additional therapeutic agents can include, e.g.,chemotherapeutics, anti-inflammatory agents, steroids,immunosuppressants, as well as Bcr-Abl, Flt-3, RAF, FAK, and JAK kinaseinhibitors for treatment of BET protein-associated diseases, disordersor conditions. The one or more additional pharmaceutical agents can beadministered to a patient simultaneously or sequentially.

In some embodiments, the compounds of the invention can be used incombination with a therapeutic agent that targets an epigeneticregulator. Examples of epigenetic regulators include the histone lysinemethyltransferases, histone arginine methyl transferases, histonedemethylases, histone deacetylases, histone acetylases, and DNAmethyltransferases. Histone deacetylase inhibitors include, e.g.,vorinostat.

For treating cancer and other proliferative diseases, the compounds ofthe invention can be used in combination with chemotherapeutic agents,or other anti-proliferative agents. The compounds of the invention canalso be used in combination with medical therapy such as surgery orradiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electronbeam radiotherapy, proton therapy, brachytherapy, and systemicradioactive isotopes. Examples of suitable chemotherapeutic agentsinclude any of: abarelix, aldesleukin, alemtuzumab, alitretinoin,allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase,azacitidine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib,busulfan intravenous, busulfan oral, calusterone, capecitabine,carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine,clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin,dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin,denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolonepropionate, eculizumab, epirubicin, erlotinib, estramustine, etoposidephosphate, etoposide, exemestane, fentanyl citrate, filgrastim,floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib,gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelinacetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinibmesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate,lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole,lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine,methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone,nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin,paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim,pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine,quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib,streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide,teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan,toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard,valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, andzoledronate.

For treating cancer and other proliferative diseases, the compounds ofthe invention can be used in combination with ruxolitinib.

For treating autoimmune or inflammatory conditions, the compound of theinvention can be administered in combination with a corticosteroid suchas triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone,or flumetholone.

For treating autoimmune or inflammatory conditions, the compound of theinvention can be administered in combination with an immune suppressantsuch as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol,Alcon), or cyclosporine (Restasis®).

For treating autoimmune or inflammatory conditions, the compound of theinvention can be administered in combination with one or more additionalagents selected from Dehydrex™ (Holles Labs), Civamide (Opko), sodiumhyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603,Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P)(Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen),15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine,doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301,Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali),oxytetracycline (Duramycin, MOLI1901, Lantibio), CF₁₀₁ (2S, 3S, 4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbamyl,Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences),ARG103 (Agentis), RX-10045 (synthetic resolvin analog, Resolvyx), DYN15(Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4(RegeneRx), OPH-01 (Ophtalmis Monaco), PCS101 (Pericor Science), REV1-31(Evolutec), Lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551(Othera), PAI-2 (University of Pennsylvania and Temple University),pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednoletabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS-0611(Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab,mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267(TorreyPines Therapeutics), or thalidomide.

In some embodiments, the compound of the invention can be administeredin combination with one or more agents selected from an antibiotic,antiviral, antifungal, anesthetic, anti-inflammatory agents includingsteroidal and non-steroidal anti-inflammatories, and anti-allergicagents. Examples of suitable medicaments include aminoglycosides such asamikacin, gentamycin, tobramycin, streptomycin, netilmycin, andkanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin,ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin;naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin;paramomycin; colistimethate; bacitracin; vancomycin; tetracyclines;rifampin and its derivatives (“rifampins”); cycloserine; beta-lactams;cephalosporins; amphotericins; fluconazole; flucytosine; natamycin;miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen;ketorolac; suprofen; cromolyn; lodoxamide; levocabastin; naphazoline;antazoline; pheniramine; or azalide antibiotic.

Other examples of agents, one or more of which a provided compound mayalso be combined with include: a treatment for Alzheimer's Disease suchas donepezil and rivastigmine; a treatment for Parkinson's Disease suchas L-DOPA/carbidopa, entacapone, ropinirole, pramipexole, bromocriptine,pergolide, trihexyphenidyl, and amantadine; an agent for treatingmultiple sclerosis (MS) such as beta interferon (e.g., Avonex® andRebif®), glatiramer acetate, and mitoxantrone; a treatment for asthmasuch as albuterol and montelukast; an agent for treating schizophreniasuch as zyprexa, risperdal, seroquel, and haloperidol; ananti-inflammatory agent such as a corticosteroid, such as dexamethasoneor prednisone, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide,and sulfasalazine; an immunomodulatory agent, includingimmunosuppressive agents, such as cyclosporin, tacrolimus, rapamycin,mycophenolate mofetil, an interferon, a corticosteroid,cyclophosphamide, azathioprine, and sulfasalazine; a neurotrophic factorsuch as an acetylcholinesterase inhibitor, an MAO inhibitor, aninterferon, an anti-convulsant, an ion channel blocker, riluzole, or ananti-Parkinson's agent; an agent for treating cardiovascular diseasesuch as a beta-blocker, an ACE inhibitor, a diuretic, a nitrate, acalcium channel blocker, or a statin; an agent for treating liverdisease such as a corticosteroid, cholestyramine, an interferon, and ananti-viral agent; an agent for treating blood disorders such as acorticosteroid, an anti-leukemic agent, or a growth factor; or an agentfor treating immunodeficiency disorders such as gamma globulin.

Formulation, Dosage Forms and Administration

When employed as pharmaceuticals, the compounds of the invention can beadministered in the form of pharmaceutical compositions. Thesecompositions can be prepared in a manner well known in thepharmaceutical art, and can be administered by a variety of routes,depending upon whether local or systemic treatment is desired and uponthe area to be treated. Administration may be topical (includingtransdermal, epidermal, ophthalmic and to mucous membranes includingintranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalationor insufflation of powders or aerosols, including by nebulizer;intratracheal or intranasal), oral or parenteral. Parenteraladministration includes intravenous, intraarterial, subcutaneous,intraperitoneal intramuscular or injection or infusion; or intracranial,e.g., intrathecal or intraventricular, administration. Parenteraladministration can be in the form of a single bolus dose, or may be, forexample, by a continuous perfusion pump. Pharmaceutical compositions andformulations for topical administration may include transdermal patches,ointments, lotions, creams, gels, drops, suppositories, sprays, liquidsand powders. Conventional pharmaceutical carriers, aqueous, powder oroily bases, thickeners and the like may be necessary or desirable.

This invention also includes pharmaceutical compositions which contain,as the active ingredient, the compound of the invention or apharmaceutically acceptable salt thereof, in combination with one ormore pharmaceutically acceptable carriers (excipients). In someembodiments, the composition is suitable for topical administration. Inmaking the compositions of the invention, the active ingredient istypically mixed with an excipient, diluted by an excipient or enclosedwithin such a carrier in the form of, for example, a capsule, sachet,paper, or other container. When the excipient serves as a diluent, itcan be a solid, semi-solid, or liquid material, which acts as a vehicle,carrier or medium for the active ingredient. Thus, the compositions canbe in the form of tablets, pills, powders, lozenges, sachets, cachets,elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solidor in a liquid medium), ointments containing, for example, up to 10% byweight of the active compound, soft and hard gelatin capsules,suppositories, sterile injectable solutions, and sterile packagedpowders.

In preparing a formulation, the active compound can be milled to providethe appropriate particle size prior to combining with the otheringredients. If the active compound is substantially insoluble, it canbe milled to a particle size of less than 200 mesh. If the activecompound is substantially water soluble, the particle size can beadjusted by milling to provide a substantially uniform distribution inthe formulation, e.g., about 40 mesh.

The compounds of the invention may be milled using known millingprocedures such as wet milling to obtain a particle size appropriate fortablet formation and for other formulation types. Finely divided(nanoparticulate) preparations of the compounds of the invention can beprepared by processes known in the art, e.g., see International App. No.WO 2002/000196.

Some examples of suitable excipients include lactose, dextrose, sucrose,sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,tragacanth, gelatin, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. Theformulations can additionally include: lubricating agents such as talc,magnesium stearate, and mineral oil; wetting agents; emulsifying andsuspending agents; preserving agents such as methyl- andpropylhydroxy-benzoates; sweetening agents; and flavoring agents. Thecompositions of the invention can be formulated so as to provide quick,sustained or delayed release of the active ingredient afteradministration to the patient by employing procedures known in the art.

The compositions can be formulated in a unit dosage form, each dosagecontaining from about 5 to about 1,000 mg (1 g), more usually about 100mg to about 500 mg, of the active ingredient. The term “unit dosageforms” refers to physically discrete units suitable as unitary dosagesfor human subjects and other mammals, each unit containing apredetermined quantity of active material calculated to produce thedesired therapeutic effect, in association with a suitablepharmaceutical excipient.

The active compound may be effective over a wide dosage range and isgenerally administered in a pharmaceutically effective amount. It willbe understood, however, that the amount of the compound actuallyadministered will usually be determined by a physician, according to therelevant circumstances, including the condition to be treated, thechosen route of administration, the actual compound administered, theage, weight, and response of the individual patient, the severity of thepatient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal activeingredient is mixed with a pharmaceutical excipient to form a solidpreformulation composition containing a homogeneous mixture of acompound of the present invention. When referring to thesepreformulation compositions as homogeneous, the active ingredient istypically dispersed evenly throughout the composition so that thecomposition can be readily subdivided into equally effective unit dosageforms such as tablets, pills and capsules. This solid preformulation isthen subdivided into unit dosage forms of the type described abovecontaining from, for example, about 0.1 to about 1000 mg of the activeingredient of the present invention.

The tablets or pills of the present invention can be coated or otherwisecompounded to provide a dosage form affording the advantage of prolongedaction. For example, the tablet or pill can comprise an inner dosage andan outer dosage component, the latter being in the form of an envelopeover the former. The two components can be separated by an enteric layerwhich serves to resist disintegration in the stomach and permit theinner component to pass intact into the duodenum or to be delayed inrelease. A variety of materials can be used for such enteric layers orcoatings, such materials including a number of polymeric acids andmixtures of polymeric acids with such materials as shellac, cetylalcohol, and cellulose acetate.

The liquid forms in which the compounds and compositions of the presentinvention can be incorporated for administration orally or by injectioninclude aqueous solutions, suitably flavored syrups, aqueous or oilsuspensions, and flavored emulsions with edible oils such as cottonseedoil, sesame oil, coconut oil, or peanut oil, as well as elixirs andsimilar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions andsuspensions in pharmaceutically acceptable, aqueous or organic solvents,or mixtures thereof, and powders. The liquid or solid compositions maycontain suitable pharmaceutically acceptable excipients as describedsupra. In some embodiments, the compositions are administered by theoral or nasal respiratory route for local or systemic effect.Compositions can be nebulized by use of inert gases. Nebulized solutionsmay be breathed directly from the nebulizing device or the nebulizingdevice can be attached to a face masks tent, or intermittent positivepressure breathing machine. Solution, suspension, or powder compositionscan be administered orally or nasally from devices which deliver theformulation in an appropriate manner.

Topical formulations can contain one or more conventional carriers. Insome embodiments, ointments can contain water and one or morehydrophobic carriers selected from, for example, liquid paraffin,polyoxyethylene alkyl ether, propylene glycol, white vaseline, and thelike. Carrier compositions of creams can be based on water incombination with glycerol and one or more other components, e.g.,glycerinemonostearate, PEG-glycerinemonostearate and cetylstearylalcohol. Gels can be formulated using isopropyl alcohol and water,suitably in combination with other components such as, for example,glycerol, hydroxyethyl cellulose, and the like. In some embodiments,topical formulations contain at least about 0.1, at least about 0.25, atleast about 0.5, at least about 1, at least about 2, or at least about 5wt % of the compound of the invention. The topical formulations can besuitably packaged in tubes of, for example, 100 g which are optionallyassociated with instructions for the treatment of the select indication,e.g., psoriasis or other skin condition.

The amount of compound or composition administered to a patient willvary depending upon what is being administered, the purpose of theadministration, such as prophylaxis or therapy, the state of thepatient, the manner of administration, and the like. In therapeuticapplications, compositions can be administered to a patient alreadysuffering from a disease in an amount sufficient to cure or at leastpartially arrest the symptoms of the disease and its complications.Effective doses will depend on the disease condition being treated aswell as by the judgment of the attending clinician depending uponfactors such as the severity of the disease, the age, weight and generalcondition of the patient, and the like.

The compositions administered to a patient can be in the form ofpharmaceutical compositions described above. These compositions can besterilized by conventional sterilization techniques, or may be sterilefiltered. Aqueous solutions can be packaged for use as is, orlyophilized, the lyophilized preparation being combined with a sterileaqueous carrier prior to administration. The pH of the compoundpreparations typically will be between 3 and 11, more preferably from 5to 9 and most preferably from 7 to 8. It will be understood that use ofcertain of the foregoing excipients, carriers, or stabilizers willresult in the formation of pharmaceutical salts.

The therapeutic dosage of a compound of the present invention can varyaccording to, for example, the particular use for which the treatment ismade, the manner of administration of the compound, the health andcondition of the patient, and the judgment of the prescribing physician.The proportion or concentration of a compound of the invention in apharmaceutical composition can vary depending upon a number of factorsincluding dosage, chemical characteristics (e.g., hydrophobicity), andthe route of administration. For example, the compounds of the inventioncan be provided in an aqueous physiological buffer solution containingabout 0.1 to about 10% w/v of the compound for parenteraladministration. Some typical dose ranges are from about 1 μg/kg to about1 g/kg of body weight per day. In some embodiments, the dose range isfrom about 0.01 mg/kg to about 100 mg/kg of body weight per day. Thedosage is likely to depend on such variables as the type and extent ofprogression of the disease or disorder, the overall health status of theparticular patient, the relative biological efficacy of the compoundselected, formulation of the excipient, and its route of administration.Effective doses can be extrapolated from dose-response curves derivedfrom in vitro or animal model test systems.

The compositions of the invention can further include one or moreadditional pharmaceutical agents such as a chemotherapeutic, steroid,anti-inflammatory compound, or immunosuppressant, examples of which arelisted hereinabove.

The compounds of the invention can be provided with or used incombination with a companion diagnostic. As used herein, the term“companion diagnostic” refers to a diagnostic device useful fordetermining the safe and effective use of a therapeutic agent. Forexample, a companion diagnostic may be used to customize dosage of atherapeutic agent for a given subject, identify appropriatesubpopulations for treatment, or identify populations who should notreceive a particular treatment because of an increased risk of a seriousside effect.

In some embodiments, the companion diagnostic is used to monitortreatment response in a patient. In some embodiments, the companiondiagnostic is used to identify a subject that is likely to benefit froma given compound or therapeutic agent. In some embodiments, thecompanion diagnostic is used to identify a subject having an increasedrisk of adverse side effects from administration of a therapeutic agent,compared to a reference standard. In some embodiments, the companiondiagnostic is an in-vitro diagnostic or imaging tool selected from thelist of FDA cleared or approved companion diagnostic devices. In someembodiments, the companion diagnostic is selected from the list of teststhat have been cleared or approved by the Center for Devices andRadiological Health.

Labeled Compounds and Assay Methods

Another aspect of the present invention relates to labeled compounds ofthe invention (radio-labeled, fluorescent-labeled, etc.) that would beuseful not only in imaging techniques but also in assays, both in vitroand in vivo, for localizing and quantitating BET proteins in tissuesamples, including human, and for identifying BET protein ligands byinhibition binding of a labeled compound. Accordingly, the presentinvention includes BET protein assays that contain such labeledcompounds.

The present invention further includes isotopically-labeled compounds ofthe invention. An “isotopically” or “radio-labeled” compound is acompound of the invention where one or more atoms are replaced orsubstituted by an atom having an atomic mass or mass number differentfrom the atomic mass or mass number typically found in nature (i.e.,naturally occurring). Suitable radionuclides that may be incorporated incompounds of the present invention include but are not limited to ³H(also written as T for tritium), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O,¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I. Theradionuclide that is incorporated in the instant radio-labeled compoundswill depend on the specific application of that radio-labeled compound.For example, for in vitro BET protein labeling and competition assays,compounds that incorporate ³H, ¹⁴C, ⁸²Br, ¹²⁵I, ¹³¹I, or ³⁵S willgenerally be most useful. For radio-imaging applications ¹¹C, ¹⁸F, ¹²⁵I,¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br will generally be most useful.

It is to be understood that a “radio-labeled” or “labeled compound” is acompound that has incorporated at least one radionuclide. In someembodiments the radionuclide is selected from the group consisting of³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br. In some embodiments, the compoundincorporates 1, 2, or 3 deuterium atoms.

The present invention can further include synthetic methods forincorporating radio-isotopes into compounds of the invention. Syntheticmethods for incorporating radio-isotopes into organic compounds are wellknown in the art, and an ordinary skill in the art will readilyrecognize the methods applicable for the compounds of invention.

A labeled compound of the invention can be used in a screening assay toidentify/evaluate compounds. For example, a newly synthesized oridentified compound (i.e., test compound) which is labeled can beevaluated for its ability to bind a BET protein by monitoring itsconcentration variation when contacting with the BET protein, throughtracking of the labeling. For example, a test compound (labeled) can beevaluated for its ability to reduce binding of another compound which isknown to bind to a BET protein (i.e., standard compound). Accordingly,the ability of a test compound to compete with the standard compound forbinding to the BET protein directly correlates to its binding affinity.Conversely, in some other screening assays, the standard compound islabeled and test compounds are unlabeled. Accordingly, the concentrationof the labeled standard compound is monitored in order to evaluate thecompetition between the standard compound and the test compound, and therelative binding affinity of the test compound is thus ascertained.

The invention will be described in greater detail by way of specificexamples. The following examples are offered for illustrative purposes,and are not intended to limit the invention in any manner. Those ofskill in the art will readily recognize a variety of non-criticalparameters which can be changed or modified to yield essentially thesame results. The compounds of the Examples were found to be inhibitorsof one or more BET proteins as described below.

EXAMPLES

Experimental procedures for compounds of the invention are providedbelow. Preparatory LC-MS purifications of some of the compounds preparedwere performed on Waters mass directed fractionation systems. The basicequipment setup, protocols, and control software for the operation ofthese systems have been described in detail in the literature. See e.g.“Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K.Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MSConfigurations and Methods for Parallel Synthesis Purification”, K.Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.Chem., 5, 670 (2003); and “Preparative LC-MS Purification: ImprovedCompound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A.Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated weretypically subjected to analytical liquid chromatography massspectrometry (LCMS) for purity check under the following conditions:Instrument; Agilent 1100 series, LC/MSD, Column: Waters Sunfire™ C₁₈ 5μm, 2.1×5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobilephase B: 0.025% TFA in acetonitrile; gradient 2% to 80% ofB in 3 minuteswith flow rate 1.5 mL/minute.

Some of the compounds prepared were also separated on a preparativescale by reverse-phase high performance liquid chromatography (RP-HPLC)with MS detector or flash chromatography (silica gel) as indicated inthe Examples. Typical preparative reverse-phase high performance liquidchromatography (RP-HPLC) column conditions are as follows:

pH=2 purifications: Waters Sunfire™ C₁₈ 5 μm, 19×100 mm column, elutingwith mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobilephase B: 0.1% TFA in acetonitrile; the flow rate was 30 mL/minute, theseparating gradient was optimized for each compound using the CompoundSpecific Method Optimization protocol as described in the literature[see “Preparative LCMS Purification: Improved Compound Specific MethodOptimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem.,6, 874-883 (2004)]. Typically, the flow rate used with the 30×100 mmcolumn was 60 mL/minute.

pH=10 purifications: Waters XBridge C₁₈ 5 μm, 19×100 mm column, elutingwith mobile phase A: 0.15% NH₄OH in water and mobile phase B: 0.15%NH₄OH in acetonitrile; the flow rate was 30 mL/minute, the separatinggradient was optimized for each compound using the Compound SpecificMethod Optimization protocol as described in the literature [See“Preparative LCMS Purification: Improved Compound Specific MethodOptimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem.,6, 874-883 (2004)]. Typically, the flow rate used with 30×100 mm columnwas 60 mL/minute.

Example 15-(2,4-Difluorophenoxy)-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one

Step 1. 4-Bromo-5-(2,4-difluorophenoxy)-2-nitroaniline

A solution of 4-bromo-5-fluoro-2-nitroaniline (1.08 g, 4.60 mmol)[Combi-Blocks, AN-1501] and cesium carbonate (1.80 g, 5.52 mmol) indimethyl sulfoxide (5.0 mL) was treated with 2,4-difluorophenol (0.90mL, 5.53 mmol) [Acros Organics, 24320] and stirred at 80° C. for 30 min.The reaction mixture was diluted with ethyl acetate and water. Theorganic layer was separated and washed with water and brine, dried withmagnesium sulfate, filtered, and concentrated to give the desiredproduct (1.50 g, 95%) as a yellow solid that was used without furtherpurification. LCMS calculated for C₁₂H₈BrF₂N₂O₃ (M+H)⁺: m/z=345.0,347.0. found: 345.0, 346.9.

Step 2. 4-Bromo-5-(2,4-difluorophenoxy)benzene-1,2-diamine

A suspension of 4-bromo-5-(2,4-difluorophenoxy)-2-nitroaniline (0.406 g,1.18 mmol) in tetrahydrofuran (5.0 mL) was treated with iron (0.657 g,11.8 mmol), followed by acetic acid (4.9 mL, 87 mmol) and stirred at 60°C. for 1 h. The reaction mixture was diluted with ethyl acetate andquenched carefully with saturated sodium bicarbonate. The organic layerwas separated and washed again with saturated sodium bicarbonate andbrine, dried with magnesium sulfate, filtered, and concentrated to givethe desired product (371 mg, quantitative) that was used immediatelywithout further purification. LCMS calculated for C₁₂H₁₀BrF₂N₂O (M+H)⁺:m/z=315.0, 317.0. found: 315.0, 316.9.

Step 3.5-Bromo-6-(2,4-difluorophenoxy)-1,3-dihydro-2H-benzimidazol-2-one

A solution of 4-bromo-5-(2,4-difluorophenoxy)benzene-1,2-diamine (0.371g, 1.18 mmol) in ethyl acetate (5.20 mL) was treated withN,N-carbonyldiimidazole (0.23 g, 1.4 mmol) and stirred at 50° C. for 30min. The reaction mixture was treated with additionalN,N-carbonyldiimidazole (1.2 eq) and stirred at 50° C. for 1 h. Thereaction mixture was cooled to 20° C. and the heterogeneous mixture wasfiltered to give the desired product (156 mg, 39%) as a light greysolid. LCMS calculated for C₁₃H₈BrF₂N₂O₂ (M+H)⁺: m/z=341.0, 343.0.found: 341.0, 342.9.

Step 4.5-(2,4-Difluorophenoxy)-6-{6-methyl-1-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one

A suspension of6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(85.0 mg, 0.20 mmol),5-bromo-6-(2,4-difluorophenoxy)-1,3-dihydro-2H-benzimidazol-2-one (74.5mg, 0.218 mmol), potassium phosphate (0.10 g, 0.50 mmol),tris(dibenzylideneacetone)dipalladium (0) (5.0 mg, 0.006 mmol), and1,3,5,7-tetramethyl-8-phenyl-2,4,6-trioxa-8-phosphatricyclo[3.3.1.13,7]decane(6.8 g, 0.0232 mmol) in 1,4-dioxane (2 mL) and water (0.4 mL) wasdegassed with nitrogen for 5 min and stirred at 80° C. for 1 h. Thereaction mixture was diluted with ethyl acetate and water and filteredover celite. The organic layer was separated, washed with brine, driedwith magnesium sulfate, filtered, and concentrated to give a cruderesidue. Purification via preparative LCMS (XBridge C18 column, elutingwith a gradient of acetonitrile/water containing 0.1% trifluoroaceticacid, at flow rate of 60 mL/min) gave the desired product (24 mg, 18%)as an off-white foam. LCMS calculated for C₂₈H₂₁F₂N₄O₅S (M+H)⁺:m/z=563.1. found: 563.1.

Step 5.5-(2,4-Difluorophenoxy)-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one

A solution of5-(2,4-difluorophenoxy)-6-{6-methyl-1-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one(0.024 g, 0.035 mmol) in ethanol (0.4 mL, 7 mmol) was treated with 1.0 Msodium hydroxide in water (0.18 mL, 0.18 mmol) and stirred at 80° C. for30 min. Purification via preparative LCMS (XBridge C18 column, elutingwith a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flowrate of 30 mL/min) gave the desired product (3 mg, 20%). ¹H NMR (500MHz, DMSO-d₆) δ 11.93 (br s, 1H), 10.62 (br s, 2H), 7.34-7.26 (m, 1H),7.22 (d, J=2.8 Hz, 1H), 7.17 (s, 1H), 7.02-6.87 (m, 3H), 6.52 (s, 1H),6.17 (d, J=2.7 Hz, 1H), 3.50 (s, 3H); LCMS calculated for C₂₁H₁₅F₂N₄O₃(M+H)⁺: m/z=409.1. found: 409.1.

Example 26-(2,4-Difluorophenoxy)-1-methyl-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one

Step 1. N-[4-Bromo-5-(2,4-difluorophenoxy)-2-nitrophenyl]-2, 2,2-trifluoroacetamide

A suspension of 4-bromo-5-(2,4-difluorophenoxy)-2-nitroaniline (0.500 g,1.45 mmol) and triethylamine (0.404 mL, 2.90 mmol) in methylene chloride(7.0 mL) at 0° C. was treated with trifluoroacetic anhydride (0.409 mL,2.90 mmol) dropwise. The reaction mixture was stirred at rt for 30 min,diluted with water (50 mL) and was extracted with dichloromethane (2×50mL). The combined organic extracts were washed with brine, dried withsodium sulfate, filtered, and concentrated to give a light brown solid.Purification by flash column chromatography (100% hexanes to 20%EtOAc/hexanes) gave the desired product (0.637 g, 100%) as a yellowsolid. LCMS calculated for C₁₄H₇BrF₅N₂O₄ (M+H)⁺: m/z=440.9, 442.9.found: 440.6, 442.7.

Step 2. 4-Bromo-5-(2,4-difluorophenoxy)-N-methyl-2-nitroaniline

A solution ofN-[4-bromo-5-(2,4-difluorophenoxy)-2-nitrophenyl]-2,2,2-trifluoroacetamide(0.620 g, 1.40 mmol) in N,N-dimethylformamide (4.2 mL) was treated withcesium carbonate (1.37 g, 4.22 mmol) and methyl iodide (0.219 mL, 3.51mmol) and stirred at 60° C. for 12 h. The reaction mixture was dilutedwith ethyl acetate (100 mL) and washed with water (75 mL) and brine,dried with sodium sulfate, filtered, and concentrated to give theintermediate methyl trifluoroacetamide which was used immediatelywithout further purification. The intermediate methyl trifluoroacetamidewas dissolved in tetrahydrofuran (11.8 mL) and methanol (2.8 mL),treated with 1.0 M sodium hydroxide in water (4.22 mL, 4.22 mmol), andstirred at 60° C. for 15 min. The reaction mixture was concentrated toremove THF and MeOH, diluted with ethyl acetate (100 mL) and washed withwater (75 ml) and brine, dried with sodium sulfate, filtered, andconcentrated to give a yellow solid. Purification by flash columnchromatography (100% hexanes to 30% EtOAc/hexanes) gave the desiredproduct (0.414 g, 82%) as a yellow solid. LCMS calculated forC₁₃H₁₀BrF₂N₂O₃ (M+H)⁺: m/z=359.0, 361.0. found: 358.8, 360.8.

Step 3.4-[2-(2,4-difluorophenoxy)-4-(methylamino)-5-nitrophenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

This compound was synthesized according to the procedure of Example 1,step 4, using 4-bromo-5-(2,4-difluorophenoxy)-N-methyl-2-nitroanilineinstead of5-bromo-6-(2,4-difluorophenoxy)-1,3-dihydro-2H-benzimidazol-2-one. LCMScalculated for C₂₈H₂₃F₂N₄O₆S (M+H)⁺: m/z=581.1. found: 580.9.

Step 4.4-(5-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl)-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one

A solution of4-[2-(2,4-difluorophenoxy)-4-(methylamino)-5-nitrophenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(0.150 g, 0.258 mmol) in ethyl acetate (1.0 mL) was treated withmethanol (1.0 mL) and saturated aqueous ammonium chloride solution(0.225 mL, 3.36 mmol) and cooled to 0° C. The reaction mixture wastreated with zinc (0.135 g, 2.07 mmol) in two portions over 5 minutes.The reaction mixture was heated at 55° C. for 10 min, diluted withdichloromethane, filtered over Celite, and washed with dichloromethane.The filtrate was concentrated to residue. The residue was dissolved indichloromethane (30 mL), washed with saturated sodium bicarbonatesolution (20 mL), dried with sodium sulfate, filtered, and concentratedto give the desired product (0.141 g, 99%), which was used withoutfurther purification. LCMS calculated for C₂₈H₂₅F₂N₄O₄S (M+H)⁺:m/z=551.2. found: 550.9.

Step 5.6-(2,4-Difluorophenoxy)-1-methyl-5-{6-methyl-1-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one

This compound was synthesized according to the procedure of Example 1,step 3, using4-[5-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneinstead of 4-bromo-5-(2,4-difluorophenoxy)benzene-1,2-diamine. LCMScalculated for C₂₉H₂₃F₂N₄O₅S (M+H)⁺: m/z=577.1. found: 576.9.

Step 6.6-(2,4-Difluorophenoxy)-1-methyl-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one

This compound was synthesized according to the procedure of Example 1,Step 5, using6-(2,4-difluorophenoxy)-1-methyl-5-{6-methyl-1-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-oneinstead of5-(2,4-difluorophenoxy)-6-{6-methyl-1-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-onetrifluoroacetate. ¹H NMR (400 MHz, DMSO-d₆) δ 11.97 (s, 1H), 10.93 (s,1H), 7.31-7.24 (m, 1H), 7.22 (dd, J=2.8, 2.8 Hz, 1H), 7.18 (s, 1H), 7.01(s, 1H), 6.93-6.81 (m, 3H), 6.19-6.12 (m, 1H), 3.49 (s, 3H), 3.24 (s,3H); LCMS calculated for C₂₂H₁₇F₂N₄O₃(M+H)⁺: m/z=423.1. found: 423.0.

Example 34-[6-(2,4-Difluorophenoxy)-1-methyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

A suspension of4-[5-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(0.045 g, 0.082 mmol) in tetrahydrofuran (0.80 mL) was treated withethyl orthoformate (0.041 mL, 0.245 mmol) and p-toluenesulfonic acidmonohydrate (1.6 mg, 8.2 μmol) and at 50° C. for 1 h. The reactionmixture was concentrated to give a residue. This residue was dilutedwith ethyl acetate (30 mL), washed with saturated sodium bicarbonatesolution (20 mL), dried with sodium sulfate, filtered, and concentratedto give the intermediate benzimidazole which was used immediatelywithout further purification. The intermediate benzimidazole wasdissolved in ethanol (1.00 mL), treated with 1.0 M sodium hydroxide inwater (0.327 mL, 0.327 mmol), and heated at 80° C. for 1 h. The reactionmixture was purified via preparative LCMS (XBridge C18 column, elutingwith a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flowrate of 30 mL/min) to give the desired product (19.5 mg, 59%). ¹H NMR(300 MHz, DMSO-d₆) δ 11.97 (br s, 1H), 8.19 (s, 1H), 7.68 (s, 1H),7.40-7.28 (m, 1H), 7.26-7.21 (m, 2H), 7.17 (s, 1H), 7.08-6.88 (m, 2H),6.24-6.10 (m, 1H), 3.77 (s, 3H), 3.52 (s, 3H); LCMS calculated forC₂₂H₁₇F₂N₄O₂ (M+H)⁺: m/z=407.1. found: 407.1.

Example 44-[6-(2,4-Difluorophenoxy)-1,2-dimethyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

This compound was synthesized according to the procedure of Example 3using triethyl orthoacetate instead of ethyl orthoformate. ¹H NMR (300MHz, DMSO-d₆) δ 11.96 (br s, 1H), 7.54 (s, 1H), 7.37-7.26 (m, 1H),7.24-7.21 (m, 1H), 7.19 (s, 1H), 7.16 (s, 1H), 6.96-6.84 (m, 2H),6.20-6.09 (m, 1H), 3.67 (s, 3H), 3.51 (s, 3H), 2.51 (s, 3H); LCMScalculated for C₂₃H₁₉F₂N₄O₂(M+H)⁺: m/z=421.1. found: 421.1.

Example 54-[5-(2,4-Difluorophenoxy)-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-onetrifluoroacetate

Step 1.4-[4,5-Diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

This compound was synthesized according to the procedure of Example 1,Step 4, using 4-bromo-5-(2,4-difluorophenoxy)benzene-1,2-diamine insteadof 5-bromo-6-(2,4-difluorophenoxy)-1,3-dihydro-2H-benzimidazol-2-one.LCMS calculated for C₂₇H₂₃F₂N₄O₄S (M+H)⁺: m/z=537.1. found: 537.1.

Step 2.4-[5-(2,4-Difluorophenoxy)-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-onetrifluoroacetate

This compound was synthesized according to the procedure of Example 3,using4-[4,5-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneinstead of4-[5-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one.¹H NMR (500 MHz, DMSO-d₆) δ 12.01 (s, 1H), 8.99 (br s, 1H), 7.79 (s,1H), 7.49-7.36 (m, 1H), 7.30 (s, 1H), 7.28-7.24 (m, 1H), 7.22-7.12 (m,2H), 7.08-6.99 (m, 1H), 6.28-6.16 (m, 1H), 3.55 (s, 3H); LCMS calculatedfor C₂₁H₁₅F₂N₄O₂(M+H)⁺: m/z=393.1. found: 393.1.

Example 64-[5-(2,4-Difluorophenoxy)-2-methyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-onetrifluoroacetate

This compound was synthesized according to the procedure of Example 3,using4-[4,5-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneand triethyl orthoacetate instead of4-[5-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneand ethyl orthoformate. ¹H NMR (500 MHz, DMSO-d₆) δ 12.02 (s, 1H), 7.75(s, 1H), 7.46-7.35 (m, 1H), 7.29 (s, 1H), 7.27-7.24 (m, 1H), 7.18-7.09(m, 2H), 7.07-7.00 (m, 1H), 6.22-6.13 (m, 1H), 3.54 (s, 3H), 2.71 (s,3H); LCMS calculated for C₂₂H₁₇F₂N₄O₂(M+H)⁺: m/z=407.1. found: 407.1.

Example 75-(2,4-Difluorophenoxy)-1,3-dimethyl-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one

A solution of6-(2,4-difluorophenoxy)-1-methyl-5-{6-methyl-1-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one(50.4 mg, 0.0874 mmol) in N,N-dimethylformamide (0.415 mL) was treatedwith sodium hydride (7.0 mg, 0.175 mmol) and stirred rt for 30 min. Thereaction mixture was treated with methyl iodide (8.2 μL, 0.131 mmol) andstirred for 1 h. The reaction mixture was quenched with saturatedammonium chloride (20 mL) and extracted with ethyl acetate (30 mL). Theorganic layer was separated, washed with brine, dried with sodiumsulfate, filtered, and concentrated to give the intermediatedimethylurea which was used immediately without further purification.The intermediate dimethylurea was dissolved in ethanol (1.0 mL), treatedwith 1.0 M sodium hydroxide in water (0.350 mL, 0.350 mmol), and heatedat 80° C. for 30 min. The reaction mixture was quenched with acetic acid(0.0224 mL, 0.393 mmol) and purified via preparative LCMS (XBridge C18column, eluting with a gradient of acetonitrile/water containing 0.1%trifluoroacetic acid, at flow rate of 60 mL/min) to give the desiredproduct which still contained an impurity. This material was re-purifiedvia preparative LCMS (XBridge C18 column, eluting with a gradient ofmethanol/water containing 0.1% trifluoroacetic acid, at flow rate of 60mL/min) to give the desired product (7.3 mg, 19%) as a white solid. ¹HNMR (500 MHz, DMSO-d₆) δ 11.97 (s, 1H), 7.32-7.26 (m, 1H), 7.26-7.22 (m,2H), 7.19 (s, 1H), 6.95 (s, 1H), 6.92-6.83 (m, 2H), 6.19 (s, 1H), 3.50(s, 3H), 3.34 (s, 3H), 3.29 (s, 3H); LCMS calculated forC₂₃H₁₉F₂N₄O₃(M+H)⁺: m/z=437.1. found: 437.1.

Example 84-(5-(2,4-difluorophenoxy)-1H-benzo[d][1,2,3]triazol-6-yl)-6-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one

Step 1. 6-Bromo-5-(2,4-difluorophenoxy)-1H-1,2,3-benzotriazole

A solution of 4-bromo-5-(2,4-difluorophenoxy)benzene-1,2-diamine (0.071g, 0.22 mmol) in acetic acid (0.4 mL) was treated with water (1.1 mL)followed by sodium nitrite (0.078 g, 1.1 mmol) and stirred at 20° C. for30 min. The reaction mixture was diluted with ethyl acetate and water.The organic layer was separated, washed with saturated sodiumbicarbonate (2×) and brine, dried with magnesium sulfate, filtered, andconcentrated to give a crude brown oil. Purification by flash columnchromatography (100% hexanes to 60% EtOAc/hexanes) gave the desiredproduct (57 mg, 78%) as a yellow solid. LCMS calculated for C₁₂H₇BrF₂N₃O(M+H)⁺: m/z=326.0, 328.0. found: 325.9, 327.9.

Step 2.6-Bromo-5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,3-benzotriazole

A solution of 6-bromo-5-(2,4-difluorophenoxy)-1H-1,2,3-benzotriazole(0.047 g, 0.14 mmol) and p-toluenesulfonic acid monohydrate (0.0027 g,0.014 mmol) in chloroform (0.65 mL) was treated with dihydropyran(0.0197 mL, 0.216 mmol) and stirred at 60° C. for 1 h. The reactionmixture was diluted with dichloromethane and washed with saturatedsodium bicarbonate. The aqueous layer was separated and re-extractedwith dichloromethane. The combined organic layers were separated, washedwith water and brine, dried with magnesium sulfate, filtered, andconcentrated to a crude oil. Purification by flash column chromatography(100% hexanes to 60% EtOAc/hexanes) gave the desired product as amixture of isomers that was used without further purification.

Step 3.4-(5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzo[d][1,2,3]triazol-6-yl)-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one

A solution of6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(0.0720 g, 0.168 mmol),6-bromo-5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,3-benzotriazole(0.069 g, 0.17 mmol),4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(1.8 mg, 0.00252 mmol), and cesium fluoride (0.0894 g, 0.589 mmol) in1-butanol (0.765 mL) and water (0.18 mL) was degassed with nitrogen for5 min and stirred at 110° C. for 1 h. The reaction mixture was dilutedwith ethyl acetate and water. The organic layer was separated and washedwith brine, dried with magnesium sulfate, filtered, and concentrated togive a crude residue. Purification by flash column chromatography (100%hexanes to 80% EtOAc/hexanes) gave the desired product (77 mg, 72%) as ayellow solid that was not entirely pure. This material was used withoutfurther purification. LCMS calculated for C₃₂H₂₈F₂N₅O₅S (M+H)⁺:m/z=632.2. found: 632.1.

Step 4.4-[5-(2,4-Difluorophenoxy)-1H-1,2,3-benzotriazol-6-yl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

A solution of4-[5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,3-benzotriazol-6-yl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(0.077 g, 0.12 mmol) in methanol (0.34 mL) was treated with 6.0 Mhydrogen chloride in water (0.102 mL, 0.610 mmol) and stirred at 20° C.for 22 h. The reaction mixture was concentrated to give a crude residuethat was used immediately without further purification.

Step 5.4-(5-(2,4-difluorophenoxy)-1H-benzo[d][1,2,3]triazol-6-yl)-6-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one

A solution of4-[5-(2,4-difluorophenoxy)-1H-1,2,3-benzotriazol-6-yl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(67 mg, 0.12 mmol) in ethanol (7.1 mL) was treated with 3.0 M sodiumhydroxide in water (408 μL, 1.22 mmol) and stirred at 20° C. overnight.Purification via preparative LCMS (XBridge C18 column, eluting with agradient of acetonitrile/water containing 0.1% trifluoroacetic acid, atflow rate of 60 mL/min) gave the desired product (21 mg, 34%). ¹H NMR(400 MHz, DMSO-d₆) δ 12.06 (s, 1H), 8.01 (br s, 1H), 7.53-7.41 (m, 1H),7.36 (s, 1H), 7.33-7.21 (m, 2H), 7.16-6.98 (m, 2H), 6.24 (d, J=2.0 Hz,1H), 3.56 (s, 3H); LCMS calculated for C₂₀H₁₄F₂N₅O₂ (M+H)⁺: m/z=394.1.found: 394.1.

Example 94-[6-(2,4-Difluorophenoxy)-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-onetrifluoroacetate

Step 1. 5-Bromo-1,4-dimethyl-3-nitropyridin-2(1H)-one

A solution of 5-bromo-4-methyl-3-nitropyridin-2-ol (15.00 g, 64.37 mmol)[Combi-Blocks, AN-1086] in N,N-dimethylformamide (250 mL) was treatedwith sodium hydride (3.09 g, 77.3 mmol) (60% dispersion on mineral oil)slowly and portionwise, and stirred at RT for 30 min. The reactionmixture was treated with methyl iodide (4.81 mL, 77.2 mmol) dropwise andstirred at RT for 3 h. LCMS indicated a clean peak for methylatedproduct. The reaction mixture was poured over water/ice (˜400 mL) andallowed to stir while the ice melted. The aqueous mixture was extractedwith EA. The organic layer was washed with water (3×) and brine, driedwith magnesium sulfate, filtered, and concentrated to give the desiredproduct (14.9 g, 93%) that was used without further purification. LCMScalculated for C₇H₈BrN₂O₃ (M+H)⁺: m/z=247.0, 249.0. found: 247.0, 248.9.

Step 2. 4-Bromo-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one

A solution of 3-amino-5-bromo-1,4-dimethylpyridin-2(1H)-one (12.1 g,55.9 mmol) in toluene (300 mL) was treated with acetic anhydride (15.8mL, 168 mmol) followed by potassium acetate (6.58 g, 67.1 mmol) andstirred at RT overnight. The reaction mixture was treated with amylnitrite (11.3 mL, 83.8 mmol) and heated at 80° C. overnight. Thereaction mixture was diluted with ethyl acetate, washed with water andbrine, dried with magnesium sulfate, filtered, and concentrated to givea mixture of the desired product along with the acetylated desiredproduct. This mixture was diluted with methanol (490 mL) and treatedwith 1.0 M sodium hydroxide in water (280 mL) and stirred at RT for 1 h.The reaction mixture was diluted with ethyl acetate, washed with waterand brine, dried with magnesium sulfate, filtered, and concentrated togive crude product. Purification by flash column chromatography (100%hexanes to 100% EtOAc) gave the desired product (8.4 g, 66%). LCMScalculated for C₇H₇BrN₃O (M+H)⁺: m/z=228.0, 230.0. found: 227.9, 229.9.

Step 3.4-Bromo-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-oneand4-bromo-6-methyl-2-{[2-(trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one

A solution of4-bromo-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (5.40 g,23.7 mmol) in N,N-dimethylformamide (170 mL) at 0° C. was treated withsodium hydride (1.42 g, 35.5 mmol) and stirred at 0° C. for 30 min. Thereaction mixture was treated with [β-(trimethylsilyl)ethoxy]methylchloride (7.90 g, 47.4 mmol) and stirred at 0° C. for 1 h. The reactionmixture was poured into ethyl acetate (200 mL) and washed with saturatedsodium bicarbonate solution. The aqueous layer was separated andextracted with ethyl acetate (2×100 mL). The combined organic layerswere washed with water (3×) and brine, dried with magnesium sulfate,filtered, and concentrated to give the crude product. Purification byflash column chromatography (100% hexanes to 100% EtOAc) gave a majorproduct and a minor product (8.5 g total yield, quantitative) as a ˜4:1mixture of SEM-protected isomers. ¹H NMR analysis of the individualproducts revealed the major isomer was consistent with the SEM group atthe 1-position and the minor isomer was consistent with the SEM group atthe 2-position. In practice, the isomers were not separated at this stepand used as a mixture of isomers in the next step. LCMS calculated forC₁₃H₂₁BrN₃O₂Si (M+H)⁺: m/z=358.1, 360.1. found: 358.0, 360.0.

Step 4.6-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-oneand6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-{[2-(trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one

A suspension of4-bromo-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-oneand 4-bromo-6-methyl-2-{[2-(trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (8.50 g, 23.7 mmol) (˜4:1mixture of isomers), 4,4,5,5,4′,4′,5′,5′-cctamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl](12.0 g, 47.5mmol), dicyclohexyl(2′,4′, 6′-triisopropylbiphenyl-2-yl)phosphine (1.23g, 2.58 mmol), potassium acetate (5.12 g, 52.2 mmol), andtris(dibenzylideneacetone)dipalladium(0) (543 mg, 0.592 mmol) in1,4-dioxane (120 mL) was degassed with nitrogen for 10 min and stirredat 80° C. for 3 h. The reaction mixture was diluted with ethyl acetate(100 mL) and saturated sodium bicarbonate solution (100 mL), filteredover Celite, and washed with ethyl acetate. The aqueous layer wasseparated and re-extracted with ethyl acetate (100 mL). The combinedorganic layers were washed with brine, dried with magnesium sulfate,filtered, and concentrated to give a crude residue. Purification byflash column chromatography (100% hexanes to 60% EtOAc/hexanes) gave theindividual isomers of the desired product (major isomer: 5.23 g, 54%;minor isomer: 1.28 g, 13%). Major isomer (SEM at 1-position): LCMScalculated for C₁₉H₃₃BN₃O₄Si (M+H)⁺: m/z=406.2. found: 406.2; minorisomer (SEM at 2-position): LCMS calculated for C₁₉H₃₃BN₃O₄Si (M+H)⁺:m/z=406.2. found: 406.2.

Step 5. 6-Bromo-5-(2,4-difluorophenoxy)-1H-benzimidazole

A solution of 4-bromo-5-(2,4-difluorophenoxy)benzene-1,2-diamine (0.090g, 0.28 mmol) in tetrahydrofuran (1.1 mL) was treated with ethylorthoformate (0.142 mL, 0.857 mmol) followed by p-toluenesulfonic acidmonohydrate (0.005 g, 0.03 mmol) and stirred at 50° C. for 1 h. Thereaction mixture was concentrated and diluted with ethyl acetate andsaturated sodium bicarbonate. The organic layer was separated and washedwith brine, dried with magnesium sulfate, filtered, and concentrated togive a crude oil. Purification by flash column chromatography (100%hexanes to 100% EtOAc) gave the desired product (69 mg, 74%). LCMScalculated for C₁₃H₈BrF₂N₂O (M+H)⁺: m/z=325.0, 327.0. found: 325.0,327.0.

Step 6.6-Bromo-5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazoleand5-bromo-6-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazole

A solution of 6-bromo-5-(2,4-difluorophenoxy)-1H-benzimidazole (0.041 g,0.13 mmol) and p-toluenesulfonic acid monohydrate (0.0024 g, 0.013 mmol)in chloroform (0.57 mL) was cooled to 0° C., treated with dihydropyran(0.0172 mL, 0.189 mmol), and stirred at 60° C. for 6 h. The reactionmixture was diluted with dichloromethane and washed with saturatedsodium bicarbonate. The aqueous layer was separated and re-extractedwith dichloromethane. The combined organic layers were separated, washedwith water and brine, dried with magnesium sulfate, filtered, andconcentrated to a crude oil. Purification by flash column chromatography(100% hexanes to 50% EtOAc/hexanes) gave the desired product (35 mg,68%) as a mixture of isomers. LCMS calculated for C₁₈H₁₆BrF₂N₂O₂ (M+H)⁺:m/z=409.0, 411.0. found: 409.0, 411.0.

Step 7.4-[6-(2,4-Difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazol-5-yl]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-oneand4-[5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazol-6-yl]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one

A suspension of6-bromo-5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazoleand5-bromo-6-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazole(0.0350 g, 0.0855 mmol) (mixture of isomers from step 6), cesiumfluoride (0.0455 g, 0.299 mmol), and6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one(0.0381 g, 0.0941 mmol) in 1-butanol (0.39 mL) and water (0.091 mL) wasdegassed with nitrogen for 5 min, treated with4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(0.908 mg, 0.00128 mmol), degassed with nitrogen for 5 min, and heatedat 100° C. for 2 h. The reaction mixture was poured into ethyl acetate(35 mL), washed with water and brine, dried with sodium sulfate,filtered, and concentrated to a crude oil. Purification by flash columnchromatography (100% hexanes to 30% ethyl acetate [containing 5%MeOH]/70% hexanes over 1 min and then 30% ethyl acetate [containing 5%MeOH]/70% hexanes to 100% ethyl acetate [containing 5% MeOH] over 30min) gave the desired product (33 mg, 63%) as a mixture of isomers. LCMScalculated for C₃₁H₃₆F₂N₅O₄Si (M+H)⁺: m/z=608.2. found: 608.2.

Step 8.4-[6-(2,4-Difluorophenoxy)-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-onetrifluoroacetate

A solution of4-[6-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazol-5-yl]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (0.033 g, 0.054 mmol) and4-[5-(2,4-difluorophenoxy)-1-(tetrahydro-2H-pyran-2-yl)-1H-benzimidazol-6-yl]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one(0.033 g, 0.054 mmol) (mixture of isomers from step 7) in methanol (0.48mL) was treated with 6.0 M hydrogen chloride in water (0.0905 mL, 0.543mmol) and stirred at 60° C. for 4 h. The reaction mixture was cooled to0° C., quenched with concentrated ammonium hydroxide, and purified viapreparative LCMS (XBridge C18 column, eluting with a gradient ofacetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of60 mL/min) to give the desired product (16 mg, 59%) as a white solid. ¹HNMR (400 MHz, DMSO-d₆) δ 9.18 (s, 1H), 7.86 (d, J=12.6 Hz, 2H),7.52-7.44 (m, 1H), 7.43 (s, 1H), 7.36-7.27 (m, 1H), 7.17 (s, 1H),7.14-7.06 (m, 1H), 3.58 (s, 3H); LCMS calculated for C₂₀H₁₄F₂N₅O₂(M+H)⁺: m/z=394.1. found: 394.1.

Example 104-[6-(2,4-Difluorophenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one

Step 1.5-Bromo-6-(2,4-difluorophenoxy)-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-one

A solution of5-bromo-6-(2,4-difluorophenoxy)-1,3-dihydro-2H-benzimidazol-2-one (0.106g, 0.311 mmol) in N,N-dimethylformamide (2.2 mL) was treated with sodiumhydride (0.0273 g, 0.684 mmol) and stirred at 20° C. for 30 min. Thereaction mixture was treated with methyl iodide (0.0426 mL, 0.684 mmol)and stirred 20° C. for 30 min. The reaction mixture was diluted withwater which resulted in the formation of a precipitate. The solid wasfiltered and washed with water to give the desired product (108 mg, 94%)which was used without further purification. LCMS calculated forC₁₅H₁₂BrF₂N₂O₂ (M+H)⁺: m/z=369.0, 371.0. found: 368.9, 371.0.

Step 2.4-[6-(2,4-Difluorophenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one

This compound was synthesized according to the procedure of Example 9,Step 7, using5-bromo-6-(2,4-difluorophenoxy)-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-oneas the starting material. LCMS calculated for C₂₈H₃₂F₂N₅O₄Si (M+H)⁺:m/z=568.1. found: 568.1.

Step 3.4-[6-(2,4-Difluorophenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one

This compound was synthesized according to the procedure of Example 9,Step 8, using4-[6-(2,4-difluorophenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-oneas the starting material. ¹H NMR (300 MHz, DMSO-d₆) δ 7.80 (s, 1H),7.35-7.24 (m, 3H), 6.98 (s, 1H), 6.94-6.85 (m, 2H), 3.53 (s, 3H), 3.36(s, 3H), 3.29 (s, 3H); LCMS calculated for C₂₂H₁₈F₂N₅O₃ (M+H)⁺:m/z=438.1. found: 438.0.

Example 114-[5-(Cyclobutylmethoxy)-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

Step 1. 4-Bromo-5-(cyclobutylmethoxy)-2-nitroaniline

Sodium hydride (0.82 g, 60% w/w, 20 mmol) was added at 0° C. to asolution of cyclobutylmethanol (1.8 mL, 20 mmol) in THF (40 mL). The 0°C. bath was removed, and the reaction mixture was stirred for 30 min.The reaction mixture was again cooled to 0° C. with an ice bath, and4-bromo-5-fluoro-2-nitroaniline (2.5 g, 11 mmol) was added. The ice bathwas removed, and the reaction mixture was stirred for 18 h at roomtemperature. The reaction was quenched with sat. NH₄Cl and then dilutedwith H₂O. The aqueous solution was extracted with EtOAc (125 mL), andthe organic layer was separated and washed with brine (100 mL). Theresulting organic layer was dried over MgSO₄, filtered, andconcentrated. Recrystallization from CH₂Cl₂/hexanes upon cooling at 0°C. overnight afforded the title compound as a red-brown solid (2.3 g,72%). ¹H NMR (300 MHz, CDCl₃) δ 8.28 (d, J=1.0 Hz, 1H), 6.07 (s, 1H),3.90 (d, J=6.0 Hz, 2H), 2.88-2.61 (m, 1H), 2.09 2.25-2.00 (m, 2H),2.01-1.71 (m, 4H). LCMS calculated for C₁₁H₁₄BrN₂O₃(M+H)⁺: m/z=301.0,303.0. found: 301.1, 303.1.

Step 2.4-[4-Amino-2-(cyclobutylmethoxy)-5-nitrophenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

A 1-dram vial was charged with4-bromo-5-(cyclobutylmethoxy)-2-nitroaniline (35.7 mg, 0.118 mmol),cesium fluoride (64 mg, 0.42 mmol),6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(50 mg, 0.12 mmol), 1-butanol (0.53 mL), and water (0.12 mL). Themixture was degassed with N₂ for 5 min. Then4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(1.2 mg, 0.0017 mmol) was added and the solvent was again degassed for 5min. The vial was capped, and the mixture was heated at 100° C. for 1.5h. The reaction mixture was diluted with EtOAc (10 mL), and theresulting solution was washed successively with water (10 mL) and brine(10 mL). The resulting organic layer was dried over Na₂SO₄, filtered,and concentrated. The product was isolated via preparative HPLC on aC-18 column (pH 2, eluting with 51-71% 0.1% TFA (aq)/MeCN over 5 min, 60mL/min). Fractions containing the title compound were combined anddiluted with EtOAc. The resulting solution was washed twice with sat.NaHCO₃ and then once with brine. The organic layer was concentrated togive the title compound as a yellow-orange solid (21 mg, 21%). LCMScalculated for C₂₆H₂₇N₄O₆S (M+H)⁺: m/z=523.2. found: 523.1.

Step 3.4-[5-(Cyclobutylmethoxy)-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

To a suspension of4-[4-amino-2-(cyclobutylmethoxy)-5-nitrophenyl]-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(21 mg, 0.024 mmol) in 1:1 EtOAc/MeOH (0.840 mL) was added saturatedsolution of NH₄Cl in water (0.0470 mL). The mixture was cooled to 0° C.,followed by addition of zinc powder (26 mg, 0.40 mmol). The reactionmixture was allowed to warm to room temperature, and the suspension wassubsequently heated at 55° C. for 1 h. The reaction mixture was dilutedwith CH₂Cl₂ and filtered through Celite. The filter cake was rinsed withCH₂Cl₂. The filtrate was then washed with saturated solution of NaHCO₃,dried over Na₂SO₄, filtered, and concentrated to provide the crudeintermediate as a brown oil. The crude intermediate was then dissolvedin THF (0.52 mL), followed by the addition of ethyl orthoformate (0.020mL, 0.12 mmol) and p-toluenesulfonic acid monohydrate (1.2 mg, 0.0063mmol). The mixture was heated at 55° C. for 1 h. The reaction mixturewas then concentrated. The resulting residue was diluted with EtOAc (4ml) and washed with saturated solution of NaHCO₃ (5 mL). The organiclayer was separated, and the aqueous layer was extracted with EtOAc (2×4mL). The combined organic layers were dried over Na₂SO₄, filtered, andconcentrated to afford the crude intermediate as a tan solid. The crudeintermediate from above was dissolved in ethanol (0.630 mL). 1.0 Msolution of NaOH (aq) (0.376 mL, 0.376 mmol) was subsequently added, andthe reaction mixture was heated at 55° C. for 4 h. The reaction mixturewas diluted with MeOH, and the product was isolated via preparative HPLCon a C-18 column (pH 10, eluting with 23-43% 0.1% NH₄OH (aq)/MeCN over 5min, 60 mL/min) to give the title compound as a white solid (2.4 mg,29%). ¹H NMR (300 MHz, CD₃OD) δ 8.11 (s, 1H), 7.59 (br s, 1H), 7.31 (d,J=2.8 Hz, 1H), 7.24 (br s, 1H), 7.21 (s, 1H), 6.22 (d, J=2.8 Hz, 1H),3.93 (d, J=5.9 Hz, 2H), 3.71 (s, 3H), 2.71-2.51 (m, 1H), 2.00-1.59 (m,6H). LCMS calculated for C₂₀H₂₁N₄O₂ (M+H)⁺: m/z=349.2. found: 349.1.

Examples 12 and 134-[5-(Cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneand4-[6-(Cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

Step 1. 5-Bromo-6-(cyclobutylmethoxy)-1H-benzimidazole

To a suspension of 4-bromo-5-(cyclobutylmethoxy)-2-nitroaniline (0.4967g, 1.649 mmol) in 1:1 ethyl acetate/methanol (17.2 mL) was addedsaturated NH₄Cl solution (1.9 mL). The mixture was cooled to 0° C. inice bath, and then zinc powder (0.9 g, 10 mmol) was added in twoportions over 2 minutes. The reaction mixture was stirred for 5 min, theice bath was removed, and the flask was allowed to warm to roomtemperature. The suspension was then stirred for 1 h at 55° C. Thereaction mixture was diluted with CH₂Cl₂, filtered through a Celiteplug, and the filter cake was washed with CH₂Cl₂. The resulting filtratewas washed with saturated solution of NaHCO₃. The aqueous layer was thenextracted with CH₂Cl₂ (50 mL). The combined organic layers were driedover Na₂SO₄, filtered, and concentrated to afford the crude intermediateas a dark purple oil. To a solution of the crude intermediate in THF (20mL) was added ethyl orthoformate (0.88 mL, 5.3 mmol) andp-toluenesulfonic acid monohydrate (54.5 mg, 0.286 mmol). The mixturewas heated for 1 h at 55° C. The reaction mixture was concentrated, andthe resulting residue was diluted with EtOAc (25 ml). This solution waswashed with saturated solution of NaHCO₃ (25 mL), and the aqueous layerwas subsequently extracted with EtOAc (2×20 mL). The combined organiclayers were dried over MgSO₄, filtered, and concentrated.Recrystallization from 9:1 CH₂Cl₂/MeOH and hexanes afforded the titlecompound as a yellow solid (0.2280 g) after collection via filtration.The remaining filtrate was concentrated and suspended in MeOH and 1 Msolution of HCl (aq) (60 mL). The aqueous solution was extracted withEt₂O (3×30 mL). The aqueous layer was then adjusted to pH 9 using solidK₂CO₃. The aqueous layer was extracted with CH₂Cl₂ (3×40 mL). Thecombined organic layers were dried over MgSO₄, filtered, andconcentrated to afford a second portion of the title compound as ayellow-brown solid (0.1275 g, 77% overall). ¹H NMR (400 MHz, CD₃OD) δ8.09 (s, 1H), 7.78 (s, 1H), 7.19 (s, 1H), 4.01 (d, J=6.0 Hz, 2H),2.91-2.76 (m, 1H), 2.23-2.11 (m, 2H), 2.10-1.93 (m, 4H). LCMS calculatedfor C₁₂H₁₄BrN₂O (M+H)⁺: m/z=281.0, 283.0. found: 281.0, 283.0.

Step 2. 5-Bromo-6-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazoletrifluoroacetate and6-bromo-5-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazole trifluoroacetate

To a 1-dram vial containing a solution of5-bromo-6-(cyclobutylmethoxy)-1H-benzimidazole (39.7 mg, 0.141 mmol) inDMF (1.3 mL) was added cesium carbonate (230 mg, 0.71 mmol), followed bydropwise addition of iodoethane (28 μL, 0.36 mmol). The reaction vesselwas sealed and placed in a 60° C. heating block for 1 h. The reactionmixture was diluted with EtOAc and washed with water (2×) and thenbrine. The organic layer was dried over MgSO₄, filtered, andconcentrated. The product was purified by preparative HPLC on a C-18column eluting with water/MeCN buffered at pH 2 with trifluoroaceticacid to give a mixture of the two title compounds (39.9 mg, 67%). LCMScalculated for C₁₄H₁₈BrN₂O (M+H)⁺: m/z=309.1, 311.1. found: 309.0,311.0.

Step 3.4-[5-(Cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneand4-[6-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

A 1-dram vial was charged with a mixture of6-bromo-5-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazole trifluoroacetateand 6-bromo-5-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazoletrifluoroacetate (39.9 mg, 0.129 mmol), cesium fluoride (77 mg, 0.51mmol),6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(57.6 mg, 0.134 mmol), 1-butanol (1.0 mL), and water (0.23 mL). Themixture was degassed with N₂ for 5 min. Then4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(4.6 mg, 0.0065 mmol) was added. The solvent was degassed again for 5min. The vial was capped, and the reaction mixture was heated at 100° C.for 1.5 h. The reaction mixture was diluted with EtOAc (4 mL) and washedwith water (3 mL) and then brine (3 mL). The organic layer were dried bypassing through a plug of Na₂SO₄ and then concentrated to afford thecrude intermediate. The crude intermediate was suspended in ethanol (2.0mL), and 3.0 M solution of NaOH (aq) (0.42 mL, 1.3 mmol) was added. Thereaction mixture was stirred at 55° C. for 1 h. The reaction mixture wasdiluted with MeCN, filtered, and concentrated. The product was thenisolated via preparative HPLC on a C-18 column (pH 10, eluting with34-54% 0.1% NH₄OH (aq)/MeCN over 5 min, 60 mL/min) to give4-[5-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(Example 12) as a white solid (5.7 mg, 16%, first eluting peak t=3.06min) and4-[6-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Example 13) as a white solid(5.6 mg, 16%, second eluting peak t=3.86 min). Example 12: ¹H NMR (500MHz, CD₃CN) δ 7.93 (s, 1H), 7.49 (s, 1H), 7.31 (s, 1H), 7.23 (d, J=2.8Hz, 1H), 7.16 (s, 1H), 6.23 (d, J=2.9 Hz, 1H), 4.23 (q, J=7.3 Hz, 2H),3.95 (d, J=6.3 Hz, 2H), 3.61 (s, 3H), 2.68-2.47 (m, 1H), 1.98-1.69 (m,6H), 1.46 (t, J=7.3 Hz, 3H). LCMS calculated for C₂₂H₂₅N₄O₂ (M+H)⁺:m/z=377.2. found: 377.2. Example 13: ¹H NMR (500 MHz, CD₃CN) δ 7.89 (s,1H), 7.60 (s, 1H), 7.21 (br s, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 6.18 (d,J=2.7 Hz, 1H), 4.25 (q, J=7.3 Hz, 2H), 3.99 (d, J=6.3 Hz, 2H), 3.59 (s,3H), 2.69-2.54 (m, 1H), 1.99-1.66 (m, 6H), 1.49 (t, J=7.3 Hz, 3H). LCMScalculated for C₂₂H₂₅N₄O₂ (M+H)⁺: m/z=377.2. found: 377.2.

Examples 14 and 154-[5-(Cyclobutylmethoxy)-1-methyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneand4-[6-(Cyclobutylmethoxy)-1-methyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

The title compounds were prepared by methods of Examples 12 and 13 usingiodomethane in Step 2 instead of iodoethane. The product was thenisolated via preparative HPLC on a C-18 column (pH 10, gradient elutionwith 0.1% solution of NH₄OH (aq)/MeCN, 26-46% over 5 min, 60 mL/min) togive Example 14 as a white solid (1.9 mg, first eluting peak t=4.16 min)and Example 15 as a white solid (2.9 mg, second eluting peak t=4.92min).4-[5-(Cyclobutylmethoxy)-1-methyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(Example 14): LCMS calculated for C₂₁H₂₃N₄O₂ (M+H)⁺: m/z=363.2. found:363.2.4-[6-(Cyclobutylmethoxy)-1-methyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(Example 15): ¹H NMR (500 MHz, CD₃OD) δ 8.03 (s, 1H), 7.63 (s, 1H), 7.30(d, J=2.8 Hz, 1H), 7.20 (s, 1H), 7.19 (s, 1H), 6.20 (d, J=2.8 Hz, 1H),3.98 (d, J=5.9 Hz, 2H), 3.91 (s, 3H), 3.70 (s, 3H), 2.69-2.55 (m, 1H),1.96-1.61 (m, 6H). LCMS calculated for C₂₁H₂₃N₄O₂ (M+H)⁺: m/z=363.2.found: 363.2.

Examples 16 and 174-[5-(Cyclobutylmethoxy)-1-benzyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneand4-[6-(Cyclobutylmethoxy)-1-benzyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

The title compounds were prepared by methods of Examples 12 and 13 usingbenzyl bromide in Step 2. The products were then isolated viapreparative HPLC on a C-18 column (pH 10, gradient elution with 0.1%solution of NH₄OH (aq)/MeCN, 32-52% over 5 min, 60 mL/min) to give4-[5-(Cyclobutylmethoxy)-1-benzyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(Example 16) as a white solid (1.0 mg, first to elute t=4.36 min) and4-[6-(Cyclobutylmethoxy)-1-benzyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(Example 17) as a white solid (2.2 mg, second to elute t=5.38 min).Example 16: LCMS calculated for C₂₇H₂₇N₄O₂ (M+H)⁺: m/z=439.2. found:439.2. Example 17: LCMS calculated for C₂₃H₂₇N₄O₂ (M+H)⁺: m/z=439.2.found: 439.2.

Examples 18 and 194-[5-(Cyclobutylmethoxy)-1-isopropyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-oneand4-[6-(Cyclobutylmethoxy)-1-isopropyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo-[2,3-c]pyridin-7-one

The title compound was prepared by the methods of Examples 12 and 13using 2-iodopropane in Step 2 instead of iodoethane. The products werethen isolated via preparative HPLC on a C-18 column (pH 10, eluting with32-52% 0.1% NH₄OH (aq)/MeCN over 5 min, 60 mL/min) to give4-[5-(cyclobutylmethoxy)-1-isopropyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(Example 18) as a white solid (6.7 mg, first eluting peak t=3.83 min)and4-[6-(cyclobutylmethoxy)-1-isopropyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(Example 19) as a white solid (2.1 mg, second eluting peak t=4.71 min).Example 18: ¹H NMR (500 MHz, CD₃CN) δ 8.20 (s, 1H), 7.70 (s, 1H), 7.49(s, 1H), 7.42 (d, J=2.8 Hz, 1H), 7.36 (s, 1H), 6.41 (d, J=2.8 Hz, 1H),4.85 (hept, J=6.7 Hz, 1H), 4.14 (d, J=6.3 Hz, 2H), 3.80 (s, 3H), 2.79(dt, J=14.1, 6.4 Hz, 1H), 2.17-1.85 (m, 14H), 1.76 (d, J=6.7 Hz, 6H).LCMS calculated for C₂₃H₂₇N₄O₂ (M+H)⁺: m/z=391.2. found: 391.2. Example19: LCMS calculated for C₂₃H₂₇N₄O₂ (M+H)⁺: m/z=391.2. found: 391.2.

Example 204-[5-(Cyclobutylmethoxy)-2-piperidin-1-yl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

Step 1. 4-Bromo-5-(cyclobutylmethoxy)benzene-1,2-diamine

To a solution of 4-bromo-5-(cyclobutylmethoxy)-2-nitroaniline (1.027 g,3.410 mmol) ion 1:1 EtOAc/MeOH (40. mL) was added saturated aqueoussolution of NH₄Cl (3.0 mL). The suspension was cooled to 0° C. using anice bath, and zinc powder (1.8 g, 28 mmol) was added in three portionsover 10 minutes. The reaction mixture was allowed to warm to roomtemperature and stirred for 2 h. The reaction mixture was then warmed to55° C., and the reaction mixture was stirred for an additional 1 h atthat temperature. The reaction mixture was diluted with EtOAc andfiltered through Celite. The filter cake was washed with EtOAc. Thefiltrate was washed with saturated aqueous solution of NaHCO₃ (100 mL)and then brine (100 mL). The resulting organic layer was dried overNa₂SO₄, filtered, and concentrated to afford a purple oil (1.017g, >99%). LCMS calculated for C₁₁H₁₅BrN₂O (M+H)⁺: m/z=271.0, 273.0.found: 271.0, 273.0.

Step 2. 6-Bromo-5-(cyclobutylmethoxy)-2-piperidin-1-yl-1H-benzimidazole

To a solution of 4-bromo-5-(cyclobutylmethoxy)benzene-1,2-diamine (403mg, 1.49 mmol) in THF (25 mL) was added N,N-carbonyldiimidazole (0.72 g,4.4 mmol). The reaction mixture was stirred at room temperature for 1.5h. The reaction mixture was diluted with EtOAc and washed with sat. NaCl(3×33 mL). The organic layer was then dried over Na₂SO₄, filtered, andconcentrated to yield the crude intermediate. A portion of the crudeintermediate (102 mg, 0.343 mmol) was dissolved in phosphoryl chloride(0.48 mL, 5.1 mmol). The reaction mixture was heated at 95° C. for 1.5h. The reaction was diluted with EtOAc and added slowly to saturatedaqueous solution of NaHCO₃. The organic layer was separated and washedsuccessively with water and brine. The brine layer was subsequentlyextracted with EtOAc. The combined organic layers were dried over MgSO₄,filtered, and concentrated to afford the crude intermediate as a brownsolid. The crude intermediate from above was dissolved inN-methylpyrrolidinone (3 mL), piperidine (1.0 mL, 10. mmol), andtriethylamine (0.24 mL, 1.7 mmol). The reaction mixture was heated at150° C. for 25 min in a microwave. The reaction mixture was diluted withMeOH, and the product was then isolated via preparative HPLC on a C-18column (pH 10, gradient elution with 0.1% solution of NH₄OH (aq)/MeCN,47-67% over 5 min, 60 mL/min) to give the title compound as an orangeoil (62.7 mg, 58%). LCMS calculated for C₁₇H₂₃BrN₃O (M+H)⁺: m/z=364.1,366.1. found: 364.1, 366.1.

Step 3.4-[5-(Cyclobutylmethoxy)-2-piperidin-1-yl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one

A 1-dram vial was charged with6-bromo-5-(cyclobutylmethoxy)-2-piperidin-1-yl-1H-benzimidazole (18.5mg, 0.0508 mmol), cesium fluoride (31 mg, 0.20 mmol),6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(33 mg, 0.076 mmol), 1-butanol (0.44 mL), and water (0.096 mL). Themixture was degassed with N₂ for 5 min. Then4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(2.0 mg, 0.0028 mmol) was added, and the solvent was degassed again for5 min. The vial was capped, and the mixture was heated at 100° C. for1.5 h. The reaction was diluted with EtOAc (4 mL) and washed with water(3 mL) and then brine (3 mL). The organic layers were dried by passingthrough a plug of Na₂SO₄ and then concentrated to afford the crudeintermediate. The crude intermediate was suspended in ethanol (0.84 mL).3.0 M solution of NaOH (aq) (0.166 mL, 0.498 mmol) was added, and thereaction mixture was stirred at 55° C. for 1 h. The reaction mixture wasdiluted with MeOH and filtered. The product was isolated via preparativeHPLC on a C-18 column (pH 10, gradient elution with 0.1% solution ofNH₄OH (aq)/MeCN, 33-53% over 5 min, 60 mL/min) to give the titlecompound as an off-white solid (1.9 mg, 8.9%). LCMS calculated forC₂₅H₃₀N₅O₂ (M+H)⁺: m/z=432.2. found: 432.2.

Example 214-[5-(Cyclobutylmethoxy)-2-cyclopentyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-onebis(trifluoroacetate)

Step 1. 6-Bromo-5-(cyclobutylmethoxy)-2-cyclopentyl-1H-benzimidazole

A 1-dram vial was charged with6-bromo-5-(cyclobutylmethoxy)-1H-benzimidazole (30 mg, 0.11 mmol) andpotassium cyclopentyltrifluoroborate (38 mg, 0.21 mmol). The solids weredissolved in a mixture of 1:1 AcOH/water (1.4 mL) and trifluoroaceticacid (7.5 μL, 0.097 mmol). Upon dissolution, manganese(III) acetatedihydrate (76 mg, 0.28 mmol) was added. The vial was capped and placedin a 50° C. heating block for 17 h. Additional portions of potassiumcyclopentyltrifluoroborate (40 mg, 0.2 mmol) and manganese(III) acetatedihydrate (79 mg, 0.29 mmol) were subsequently added, and the reactionmixture was heated at 50° C. for 2 h. A third portion of potassiumcyclopentyltrifluoroborate (38 mg, 0.22 mmol) was added, and thereaction mixture was then heated at 50° C. for 3 h. The reaction mixturewas added dropwise to saturated solution of K₂CO₃ (4 mL). The resultingaqueous mixture was extracted with EtOAc (3×4 mL). The combined organiclayers were washed with water (3 mL) and then sat. NaCl (3 mL). Theorganic layer was then dried over MgSO₄, filtered, and concentrated. Theproduct was isolated via preparative HPLC on a C-18 column (pH 10,gradient elution with 0.1% solution of NH₄OH (aq)/MeCN, 45-65% over 5min, 60 mL/min) to give the title compound (15.2 mg, 41%). LCMScalculated for C₁₇H₂₂BrN₂O (M+H)⁺: m/z=349.1, 351.1. found: 349.1,351.1.

Step 2.4-[5-(Cyclobutylmethoxy)-2-cyclopentyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-onebis(trifluoroacetate)

A 1-dram vial was charged with6-bromo-5-(cyclobutylmethoxy)-2-cyclopentyl-1H-benzimidazole (15.2 mg,0.0435 mmol), cesium fluoride (32 mg, 0.21 mmol),6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(21 mg, 0.049 mmol), 1-butanol (0.38 mL, 4.1 mmol), and water (82 μL,4.6 mmol). The mixture was degassed with N₂ for 5 min. Then4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(1.5 mg, 0.0021 mmol) was added. The solvent was degassed again for 5min. The vial was capped, and the mixture was heated at 100° C. for 1.5h. An additional portion of6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(21 mg, 0.049 mmol) was added, and reaction mixture was degassedbriefly. The vial was capped, and the reaction mixture was stirred at100° C. for 1 h. An additional portion of4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(2.0 mg, 0.0028 mmol) was added. The vial was capped, and the reactionmixture was stirred at 100° C. for 20 h and then at room temperature for2 d. The reaction was diluted with EtOAc (4 mL), washed with water (3mL) and then sat. NaCl (3 mL). The organic layer was dried by passingthrough a plug of Na₂SO₄ and concentrated to afford the crudeintermediate. The crude intermediate was suspended in ethanol (0.715 mL,12.2 mmol). 3.0 M solution of NaOH (aq) (0.142 mL, 0.427 mmol) wasadded, and the reaction mixture was stirred at 55° C. for 1 h. Thereaction mixture was diluted with MeOH, quenched with trifluoroaceticacid (0.034 mL, 0.44 mmol), and filtered. The product was then isolatedvia preparative LCMS (pH 2, gradient elution with 0.1% solution of TFA(aq)/MeCN, 25-45% over 5 min, 60 mL/min) to give the title compound as awhite solid (2.0 mg, 7.1%). ¹H NMR (400 MHz, CD₃OD) δ 7.66 (s, 1H), 7.33(d, J=2.8 Hz, 1H), 7.29 (s, 1H), 7.27 (s, 1H), 6.18 (d, J=2.8 Hz, 1H),4.00 (d, J=5.9 Hz, 2H), 3.70 (s, 3H), 3.63-3.51 (m, 1H), 2.74-2.55 (m,1H), 2.45-2.27 (m, 2H), 2.07-1.59 (m, 12H). LCMS calculated forC₂₅H₂₉N₄O₂ (M-2TFA+H)⁺: m/z=417.2. found: 417.3.

Example 22 Ammonium3-[5-(cyclobutylmethoxy)-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1H-benzimidazol-2-yl]propanoate

Step 1. Methyl3-[5-bromo-6-(cyclobutylmethoxy)-1H-benzimidazol-2-yl]propanoatetrifluoroacetate

A mixture of 4-bromo-5-(cyclobutylmethoxy)benzene-1,2-diamine (43.3 mg,0.160 mmol) and succinic anhydride (20 mg, 0.20 mmol) in 1,4-dioxane(0.5 mL) was heated at 150° C. in a microwave for 10 minutes. Thereaction mixture was then concentrated. The resulting oil was dissolvedin 2% sulfuric acid in methanol (0.5 mL, 0.2 mmol). The reaction wasstirred at 150° C. in a microwave for 10 minutes. The reaction mixturewas diluted with MeOH and purified via preparative HPLC on a C-18 column(pH 2, gradient elution with 0.1% solution of TFA (aq)/MeCN, 37-45% over5 min, 60 mL/min) to give the title compound as a brown oil (16.6 mg,22%). LCMS calculated for C₁₆H₂₀BrN₂O₃(M-TFA+H)⁺: m/z=367.1, 369.1.found: 367.1, 369.1.

Step 2. Ammonium3-[5-(cyclobutylmethoxy)-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1H-benzimidazol-2-yl]propanoate

To a 1-dram vial was added methyl3-[6-bromo-5-(cyclobutylmethoxy)-1H-benzimidazol-2-yl]propanoatetrifluoroacetate (16.6 mg, 0.0345 mmol), cesium fluoride (27 mg, 0.18mmol),6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(21.3 mg, 0.0497 mmol), 1-butanol (0.36 mL), and water (0.084 mL). Themixture was degassed with nitrogen for 5 min. Then4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(1.7 mg, 0.0024 mmol) was added, and the solvent was degassed for 5 min.The vial was capped, and the mixture was heated at 100° C. for 1.5 h. Anadditional portion of4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1)(1.7 mg, 0.0024 mmol) and6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one(17 mg, 0.40 mmol) were added. The reaction mixture was degassedbriefly. The vial was capped, and the reaction mixture was heated at100° C. for 2 h. The reaction was diluted with EtOAc (4 mL), washed withwater (3 mL) and then brine (3 mL). The organic layers were dried bypassing through a plug of Na₂SO₄ and then concentrated to afford thecrude intermediate.

The crude intermediate was suspended in methanol (0.73 mL). 3.0 Msolution of NaOH (aq) (0.154 mL, 0.463 mmol) was added, and the reactionmixture was stirred at 55° C. for 1 h. The reaction mixture was dilutedwith MeOH and filtered. The product was isolated via preparative HPLC ona C-18 column (pH 10, gradient elution with 0.1% solution of NH₄OH(aq)/MeCN, 11-31% over 5 min, 60 mL/min) to yield a white solid (2.5 mg,16%). LCMS calculated for C₂₃H₂₅N₄O₄ (M−NH₃+H)⁺: m/z=421.2. found:421.2. ¹H NMR (400 MHz, d₆-DMSO) δ 11.89 (s, 1H), 7.33 (s, 1H), 7.21 (t,J=2.8 Hz, 1H), 7.15 (s, 1H), 7.09 (s, 1H), 6.09-6.02 (m, 1H), 3.85 (d,J=6.1 Hz, 2H), 3.52 (s, 3H), 2.42-2.43 (m, 2H), 1.89-1.59 (m, 6H).

Example A1 BRD4 AlphaScreen™ Assay

BRD4-BD1 and BRD4-BD2 assays were conducted in white 384-wellpolystyrene plate in a final volume of 20 μL for BD1 and 40 μL for BD2.Inhibitors were first serially diluted in DMSO and added to the platewells before the addition of other reaction components. The finalconcentration of DMSO in the assay was 1.25% (BD1) and 0.83% (BD2). Theassays were carried out at room temperature for 75 min. in the assaybuffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% CHAPS, 0.01% BSA),containing 50 nM Biotin-labeled tetra-acetylated histone H₄ peptide(H4Ac4), 3.8 nM (BRD4-BD1, BPS Bioscience #31040) or 20 nM (BRD4-BD2,BPS Bioscience #31041). The reaction followed by the addition of 20 μLof assay buffer supplemented with Streptavidin donor beads (PerkinElmer6760002) and GSH Acceptor beads (PerkinElmer-AL109C) at 4 g/mL underreduced light. After plate sealing, the plate was incubated in the darkat room temperature for 75 min. before reading on a PHERAstar FS platereader (BMG Labtech). IC₅₀ determination was performed by fitting thecurve of percent control activity versus the log of the inhibitorconcentration using the GraphPad Prism 5.0 software. IC₅₀ data for theExamples is presented in Table 1 as determined by Assay A1.

TABLE 1 BRD4 BD-1 BRD4 BD-2 enzyme IC₅₀ enzyme IC₅₀ Example # (nM)*(nM)* 1 + + 2 + + 3 + + 4 + + 5 + + 6 + + 7 ++ + 8 + + 9 + + 10 + +11 + + 12 + + 13 + + 14 + + 15 + + 16 ++ + 17 + + 18 + + 19 + + 20 + +21 + + 22 + + *column symbols: + refers to ≦100 nM ++ refers to >100 nMto 1000 nM

Example B1 KMS.12.BM Cell Viability Assay

KMS.12.BM cell line (human myeloma) was purchased from JCRB (Osaka,Japan) and maintained in RPMI with 10% FBS culture medium. To measurethe cytotoxic activity of the compounds through ATP quantitation, theKMS.12.BM cells are plated in the RPMI culture medium at 5000cells/well/per 100 μL into a 96-well polystyrene clear black tissueculture plate (Greiner-bio-one through VWR, NJ), in the presence orabsence of a concentration range of test compounds. After 3 days, 100 mLCell Titer-GLO Luminescent (Promega, Madison, Wis.) cell culture agentis added to each well for 10 minutes at room temperature to stabilizethe luminescent signal. This determines the number of viable cells inculture based on quantitation of the ATP present, which signals thepresence of metabolically active cells. Luminescence is measured withthe Top Count 384 (Packard Bioscience through Perkin Elmer, Boston,Mass.). Compound inhibition is determined relative to cells culturedwith no drug and the IC₅₀ is reported as the compound concentrationrequired for 50% cell death. IC₅₀ data for the Examples is presented inTable 2 as determined by Assay B1.

TABLE 2 Example # KMS cellular IC₅₀ (nM)* 1 + 2 + 3 + 4 + 5 + 6 + 7 +8 + 9 + 10 + 11 + 12 + 13 + 14 + 15 + 16 NA 17 + 18 + 19 + 20 + 21 + 22++ *column symbols: + refers to ≦1000 nM ++ refers to >1000 nM to 10000nM NA—“not available”

Example C1 KMS.12.BM C-myc ELISA Assay

KMS.12.BM cell line (human myeloma) was purchased from JCRB (Osaka,Japan) and maintained in RPMI with 10% FBS culture medium. To measurethe C-myc inhibitory activity of the compounds, the KMS.12.BM cells areplated in the RPMI culture medium at 75000 cells/well/per 200 μL into a96-well flat bottom polystyrene tissue culture plate (Corning throughVWR, N.J.), in the presence or absence of a concentration range of testcompounds. After 2 hours, cell are pelleted and lysed with CellExtraction Buffer (BioSource, Carlsbad, Calif.) in the presence ofprotease inhibitors (Life Technologies, Grand Island, N.Y. and Sigma, StLouis, Mo.). Clarified lyses are tested in a C-myc commercial ELISA(Life Technologies, Grand Island, N.Y.). Compound inhibition isdetermined relative to cells cultured with no drug and the IC₅₀ isreported as the compound concentration required for 50% C-mycinhibition. IC₅₀ data for the Examples is presented in Table 3 asdetermined by Assay C1.

TABLE 3 Example # KMS C-myc IC₅₀ (nM)* 1 + 2 + 3 + 4 + 5 + 6 + 7 NA 8 +9 + 10 + 11 + 12 NA 13 + 14 + 15 + 16 NA 17 + 18 + 19 + 20 + 21 NA 22 NA*column symbols: + refers to ≦1000 nM NA—“not available”

Various modifications of the invention, in addition to those describedherein, will be apparent to those skilled in the art from the foregoingdescription. Such modifications are also intended to fall within thescope of the appended claims. Each reference, including all patent,patent applications, and publications, cited in the present applicationis incorporated herein by reference in its entirety.

What is claimed is:
 1. A method of treating a BET-mediated cancer,wherein the cancer is leukemia, lymphoma, multiple myeloma, braincancer, neuroblastoma, carcinoma, skin cancer, lung cancer, or prostatecancer, comprising administering to a patient in need of such treatmenta therapeutically effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

represents a single or double bond; Ring B is phenyl, 5-memberedheteroaryl, 6-membered heteroaryl, C₅-cycloalkyl, C₆-cycloalkyl5-membered heterocycloalkvyl, or 6-membered heterocycloalkyl, eachoptionally substituted by 1, 2, 3, or 4 R^(B); L is absent,—(CR^(a)R^(b))_(p)—, —(CR^(a)R^(b))_(n)—O—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—S(═O)₂—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═)O—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—OC(═O)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—NR^(c)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—C(═O)NR^(c)—(CR^(a)R^(b))_(m)—,—(CR^(a)R^(b))_(n)—NR^(c)C(═O)—(CR^(a)R^(b))_(m)—, or—(CR^(a)R^(b))_(n)—NR^(c)C(═O)NR^(d)—(CR^(a)R^(b))_(m)—; A1 is CR³ or N;A2 is C or N; A3 is C or N; A4 is CR⁴ or N; wherein when one of A2 andA3 is N, then the other of A2 and A3 is C; W is CR⁵; X is CR⁶ or N; Y isCR⁷ or N; Z is C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, or 5-10 memberedheteroaryl, or 4-10 membered heterocycloalkyl, each of which isoptionally substituted by 1, 2, 3, 4, or 5 R^(Z); R¹ is H or C₁₋₄ alkyl;R² is C₁₋₄ alkyl, C₁₋₄ haloalkyl, or C₁₋₄ hydroxyalkyl; R³ and R⁴ areeach independently selected from H, halo, CN, NO₂, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl; R⁵ is H, halo, C₁₋₆ alkyl, orC₁₋₆ haloalkyl; R⁶ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C(O)R^(b1), C(O)NR^(c1)R^(d1), C(O)OR^(a1), S(O)R^(b1),S(O)NR^(c1)R^(d1), S(O)₂R^(b1), or S(O)₂NR^(c1)R^(d1), wherein said C₁₋₆alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are each optionally substituted by1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₄haloalkyl, CN, NO₂, OR^(a1), SR^(a1), C(O)R^(b1), C(O)NR^(c1)R^(d1),C(O)OR^(a1), OC(O)R^(b1), OC(O)NR^(c1)R^(d1), NR^(c1)R^(d1),NR^(c1)C(O)R^(b1), NR^(c1)C(O)OR^(a1), NR^(c1)C(O)NR^(c1)R^(d1),C(═NR^(e1))R^(b1), C(═NR^(e1))NR^(c1)R^(d1),NR^(c1)C(═NR^(e1))NR^(c1)R^(d1), NR^(c1)S(O)R^(b1), NR^(c1)S(O)₂R^(b1),NR^(c1)S(O)₂NR^(c1)R^(d1), S(O)R^(b1), S(O)NR^(c1)R^(d1), S(O)₂R^(b1),and S(O)₂NR^(c1)R^(d1); R⁷ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2),S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2), or S(O)₂NR^(c2)R^(d2),wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are eachoptionally substituted by 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₄ haloalkyl, CN, NO₂, OR^(a2), SR^(a2),C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2),OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2), C(═NR^(e2))R^(b2),C(═NR^(e2))NR^(c2)R^(d2), NR^(c2)C(═NR^(e2))NR^(c2)R^(d2),NR^(c2)S(O)R^(b2), NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2),S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2); eachR^(B) is independently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂, OR^(a3),SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), C(═NR^(e3))R^(b3),C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂, OR^(a3), SR^(a3),C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), OC(O)R^(b3),OC(O)NR^(c3)R^(d3), C(═NR^(e3))NR^(c3)R^(d3),NR^(c3)C(═NR^(e3))NR^(c3)R^(d3), NR^(c3)R^(d3), NR^(c3)C(O)R^(b3),NR^(c3)C(O)OR^(a3), NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3),NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3); each R^(Z) isindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂, OR^(a4), SR^(a4),C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4),OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), C(═NR^(e4))R^(b4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4),S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4);wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkylare each optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a4), SR^(a4), C(O)R^(b4),C(O)NR^(c4)R^(d4), C(O)OR^(a4), OC(O)R^(b4), OC(O)NR^(c4)R^(d4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)R^(d4), NR^(c4)C(O)R^(b4), NR^(c4)C(O)OR^(a4),NR^(c4)C(O)NR^(c4)R^(d4), NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4),NR^(c4)S(O)₂NR^(c4)R^(d4), S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4),and S(O)₂NR^(c4)R^(d4); each R^(a) and R^(b) is independently selectedfrom H, halo, OH, methyl, and ethyl; each R^(c) and R^(d) isindependently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄hydroxyalkyl, and cyclopropyl; each R^(a1), R^(b1), R^(c1), R^(d1),R^(a2), R^(b2), R^(c2), R^(d2), R^(a3), R^(b3), R^(c3), R^(d3), R^(a4),R^(b4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆ alkyl,C₁₋₄ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀ cycloalky-C₁₋₆ alkyl, (5-10 memberedheteroaryl)-C₁₋₆ alkyl, and (4-10 membered heterocycloalkyl)-C₁₋₆ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,C₆₋₁₀ aryl-C₁₋₆ alkyl, C₃₋₁₀ cycloalky-C₁₋₆ alkyl, (5-10 memberedheteroaryl)-C₁₋₆ alkyl, and (4-10 membered heterocycloalkyl)-C₁₋₆ alkylis optionally substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, halo, CN,OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5),OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5); or any R^(c1) and R^(d1) together with the N atom towhich they are attached form a 4-, 5-, 6-, or 7-memberedheterocycloalkyl group optionally substituted with 1, 2, or 3substituents independently selected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl,4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆haloalkyl, halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5), wherein said C₁₋₆alkyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, and5-6 membered heteroaryl are optionally substituted by 1, 2, or 3substituents independently selected from halo, CN, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5); or any R^(c2) and R^(d2) together with the N atom towhich they are attached form a 4-, 5-, 6-, or 7-memberedheterocycloalkyl group optionally substituted with 1, 2, or 3substituents independently selected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl,4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆haloalkyl, halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5), wherein said C₁₋₆alkyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, and5-6 membered heteroaryl are optionally substituted by 1, 2, or 3substituents independently selected from halo, CN, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5), andS(O)₂NR^(c5)R^(d5); or any R^(c3) and R^(d3) together with the N atom towhich they are attached form a 4-, 5-, 6-, or 7-memberedheterocycloalkyl group optionally substituted with 1, 2, or 3substituents independently selected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl,4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆haloalkyl, halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5), wherein said C₁₋₆alkyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, and5-6 membered heteroaryl are optionally substituted by 1, 2, or 3substituents independently selected from halo, CN, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5)5, andS(O)₂NR^(c5)R^(d5); or any R^(c4) and R^(d4) together with the N atom towhich they are attached form a 4-, 5-, 6-, or 7-memberedheterocycloalkyl group optionally substituted with 1, 2, or 3substituents independently selected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl,4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, 5-6 membered heteroaryl, C₁₋₆haloalkyl, halo, CN, OR^(a5), SR^(a5), C(O)R^(b5), C(O)NR^(c5)R^(d5),C(O)OR^(a5), OC(O)R^(b5), OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5),NR^(c5)C(O)R^(b5), NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5),C(═NR^(e5))NR^(c5)R^(d5), NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5),S(O)NR^(c5)R^(d5), S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5),NR^(c5)S(O)₂NR^(c5)R^(d5), and S(O)₂NR^(c5)R^(d5), wherein said C₁₋₆alkyl, C₃₋₇ cycloalkyl, 4-7 membered heterocycloalkyl, C₆₋₁₀ aryl, and5-6 membered heteroaryl are optionally substituted by 1, 2, or 3substituents independently selected from halo, CN, OR^(a5), SR^(a5),C(O)R^(b5), C(O)NR^(c5)R^(d5), C(O)OR^(a5), OC(O)R^(b5),OC(O)NR^(c5)R^(d5), NR^(c5)R^(d5), NR^(c5)C(O)R^(b5),NR^(c5)C(O)NR^(c5)R^(d5), NR^(c5)C(O)OR^(a5), C(═NR^(e5))NR^(c5)R^(d5),NR^(c5)C(═NR^(e5))NR^(c5)R^(d5), S(O)R^(b5), S(O)NR^(c5)R^(d5),S(O)₂R^(b5), NR^(c5)S(O)₂R^(b5), NR^(c5)S(O)₂NR^(c5)R^(d5)5, andS(O)₂NR^(c5)R^(d5), each R^(e1), R^(e2), R^(e3), and R^(e4) isindependently selected from H, C₁₋₄ alkyl, CN, OR^(a5), SR^(b5),S(O)₂R^(b5), C(O)R^(b5), S(O)₂NR^(c5)R^(d5), and C(O)NR^(c5)R^(d5); eachR^(a5), R^(b5), R^(c5), and R^(d5) is independently selected from H,C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, wherein saidC₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl, is optionally substitutedwith 1, 2, or 3 substituents independently selected from OH, CN, amino,halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy; each R^(e5) isindependently selected from H, C₁₋₄ alkyl, and CN; n is 0, 1, or 2; m is0, 1, or 2; and p is 1, 2, 3, or 4; wherein any aforementionedheterocycloalkyl group, including the heterocycloalkyl group of Ring B,is optionally substituted by 1 or 2 oxo groups.
 2. The method of claim1, wherein R¹ is H.
 3. The method of claim 1, wherein R² is C₁₋₄ alkyl.4. The method of claim 1, wherein R² is methyl.
 5. The method of claim1, wherein X is CR⁶.
 6. The method of claim 1, wherein Y is CR⁷.
 7. Themethod of claim 1, wherein Y is N.
 8. The method of claim 1, wherein Lis —(CR^(a)R^(b))_(n)—O—(CR^(a)R^(b))_(m)—.
 9. The method of claim 1,wherein L is O or CH₂O.
 10. The method of claim 1, wherein L is O. 11.The method of claim 1, wherein Z is C₆₋₁₀ aryl, C₃₋₇ cycloalkyl, or 5-10membered heteroaryl, each of which is optionally substituted by 1, 2, 3,4, or 5 R^(Z).
 12. The method of claim 1, wherein Z is C₆₋₁₀ aryl or5-10 membered heteroaryl, each of which is optionally substituted by 1,2, 3, 4, or 5 R^(Z).
 13. The method of claim 1, wherein Z is phenyloptionally substituted by 1, 2, 3, 4, or 5 R^(Z).
 14. The method ofclaim 1, wherein Z is C₃₋₇ cycloalkyl optionally substituted by 1, 2, 3,4, or 5 R^(Z).
 15. The method of claim 1, wherein Z is cyclobutyl. 16.The method of claim 1, wherein each R^(Z) is independently selected fromhalo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, CN, NO₂,OR^(a4), SR^(a4), C(O)R^(b4), C(O)NR^(c4)R^(d4), C(O)OR^(a4),OC(O)R^(b4), OC(O)NR^(c4)R^(d4), NR^(c4)R^(d4), NR^(c4)C(O)R^(b4),NR^(c4)C(O)OR^(a4), NR^(c4)C(O)NR^(c4)R^(d4), C(═NR^(e4))R^(b4),C(═NR^(e4))NR^(c4)R^(d4), NR^(c4)C(═NR^(e4))NR^(c4)R^(d4),NR^(c4)S(O)R^(b4), NR^(c4)S(O)₂R^(b4), NR^(c4)S(O)₂NR^(c4)R^(d4),S(O)R^(b4), S(O)NR^(c4)R^(d4), S(O)₂R^(b4), and S(O)₂NR^(c4)R^(d4). 17.The method of claim 1, wherein each R^(Z) is independently selected fromF, Cl, and Br.
 18. The method of claim 1, wherein A1 is CR³.
 19. Themethod of claim 1, wherein A2 is C.
 20. The method of claim 1, whereinA3 is C.
 21. The method of claim 1, wherein A4 is CR⁴.
 22. The method ofclaim 1, wherein the compound of Formula I is a compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein: the 5-memberedring formed by A2, A3, B1, B2, and B3 is (1) 5-membered heteroarylwherein B1, B2, and B3 are each independently selected from CH, N, NH,O, and S, (2) C₅-cycloalkyl wherein B1, B2, and B3 are eachindependently selected from CH, CH₂, and C(O), or (3) 5-memberedheterocycloalkyl wherein B1, B2, and B3 are each independently selectedfrom CH, CH₂, C(O), N, NH, O, S, S(O), and S(O)₂; and q is 0, 1, 2 or 3.23. The method of claim 22, wherein B1, B2, and B3 are eachindependently selected from CH, CH₂, C(O), N, and NH.
 24. The method ofclaim 22, wherein B1 is N or NH.
 25. The method of claim 22, wherein B1is NH.
 26. The method of claim 22, wherein B2 is N, CH, or C(O).
 27. Themethod of claim 22, wherein B3 is N or NH.
 28. The method of claim 22,wherein the compound of Formula II is a compound of Formula IIa:

or a pharmaceutically acceptable salt thereof.
 29. The method of claim22, wherein the compound of Formula II is a compound of Formula IIb:

or a pharmaceutically acceptable salt thereof.
 30. The method of claim22, wherein the compound of Formula II is a compound of Formula IIc:

or a pharmaceutically acceptable salt thereof, wherein r is 0, 1, 2, 3,4, or
 5. 31. The method of claim 22, wherein the compound of Formula IIis a compound of Formula IId, IIe, IIf, or IIg:

wherein: r is 0, 1, 2, 3, 4, or 5; and R⁸, R⁹, and R¹⁰ are eachindependently selected from H, C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, whereinsaid C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl,and 4-10 membered heterocycloalkyl are each optionally substituted with1, 2, 3, 4, or 5 substituents independently selected from halo, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl, 5-10 memberedheteroaryl, 4-10 membered heterocycloalkyl, CN, NO₂, OR^(a3), SR^(a3),C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), NR^(c3)R^(d3),NR^(c3)C(O)R^(b3), NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3),NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3).
 32. The methodof claim 31, or a pharmaceutically acceptable salt thereof, wherein R⁸,R⁹, and R¹⁰ are each independently selected from H, C₁₋₆ alkyl, C₆₋₁₀aryl, C₃₋₁₀ cycloalkyl, 5-10 membered heteroaryl, and 4-10 memberedheterocycloalkyl, wherein said C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are eachoptionally substituted with 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, CN, NO₂, OR^(a3),SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3), NR^(c3)R^(d3),NR^(c3)C(O)R^(b3), NR^(c3)C(O)NR^(c3)R^(d3), NR^(c3)S(O)R^(b3),NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3), S(O)R^(b3),S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3).
 33. The methodof claim 31, or a pharmaceutically acceptable salt thereof, wherein r is0, 1, 2, or
 3. 34. The method of claim 22, wherein the compound ofFormula II is a compound of Formula IIh:

or a pharmaceutically acceptable salt thereof.
 35. The method of claim22, wherein the compound of Formula II is a compound of Formula IIi orIIj:

or a pharmaceutically acceptable salt thereof, wherein: R⁸, R⁹, and R¹⁰are each independently selected from H, C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀cycloalkyl, 5-10 membered heteroaryl, and 4-10 memberedheterocycloalkyl, wherein said C₁₋₆ alkyl, C₆₋₁₀ aryl, C₃₋₁₀ cycloalkyl,5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are eachoptionally substituted with 1, 2, 3, 4, or 5 substituents independentlyselected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₆₋₁₀ aryl, CN, NO₂,OR^(a3), SR^(a3), C(O)R^(b3), C(O)NR^(c3)R^(d3), C(O)OR^(a3),NR^(c3)R^(d3), NR^(c3)C(O)R^(b3), NR^(c3)C(O)NR^(c3)R^(d3),NR^(c3)S(O)R^(b3), NR^(c3)S(O)₂R^(b3), NR^(c3)S(O)₂NR^(c3)R^(d3),S(O)R^(b3), S(O)NR^(c3)R^(d3), S(O)₂R^(b3), and S(O)₂NR^(c3)R^(d3). 36.The method of claim 1, wherein the compound of Formula I is a compoundof Formula III:

or a pharmaceutically acceptable salt thereof, wherein: the 6-memberedring formed by A2, A3, B4, B5, B6, and B7 is (1) phenyl, (2) 6-memberedheteroaryl wherein B4, B5, B6, and B7 are each independently selectedfrom CH and N, (3) C₆-cycloalkyl wherein B4, B5, B6, and B7 are eachindependently selected from CH, CH₂, and C(O), or (4) 6-memberedheterocycloalkyl wherein B4, B5, B6, and B7 are each independentlyselected from CH, CH₂, C(O), N, NH, O, S, S(O), and S(O)₂; and s is 0,1, 2, 3, or
 4. 37. The method of claim 1, wherein the compound isselected from:5-(2,4-difluorophenoxy)-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;6-(2,4-difluorophenoxy)-1-methyl-5-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;4-[6-(2,4-difluorophenoxy)-1-methyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[6-(2,4-difluorophenoxy)-1,2-dimethyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(2,4-difluorophenoxy)-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(2,4-difluorophenoxy)-2-methyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;and5-(2,4-difluorophenoxy)-1,3-dimethyl-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one;4-(5-(2,4-difluorophenoxy)-1H-benzo[d][1,2,3]triazol-6-yl)-6-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one;4-[6-(2,4-difluorophenoxy)-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one;and4-[6-(2,4-difluorophenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one,or a pharmaceutically acceptable salt of any of the aforementioned. 38.The method of claim 1, wherein the compound is selected from:4-[5-(cyclobutylmethoxy)-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[6-(cyclobutylmethoxy)-1-ethyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(cyclobutylmethoxy)-1-methyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[6-(cyclobutylmethoxy)-1-methyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(cyclobutylmethoxy)-1-benzyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[6-(cyclobutylmethoxy)-1-benzyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(cyclobutylmethoxy)-1-isopropyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[6-(cyclobutylmethoxy)-1-isopropyl-1H-benzimidazol-5-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(cyclobutylmethoxy)-2-piperidin-1-yl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;4-[5-(cyclobutylmethoxy)-2-cyclopentyl-1H-benzimidazol-6-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;and ammonium3-[5-(cyclobutylmethoxy)-6-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-1H-benzimidazol-2-yl]propanoate;or a pharmaceutically acceptable salt of any of the aforementioned. 39.The method of claim 1, wherein the cancer is leukemia.
 40. The method ofclaim 39, wherein the leukemia is acute eosinophilic leukemia, acuteerythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblasticleukemia, acute monocytic leukemia, acute promyelocytic leukemia, adultT-cell leukemia, aggressive NK-cell leukemia, B-cell chronic lymphocyticleukemia, B-cell prolymphocytic leukemia, hairy cell leukemia, acutelymphocytic leukemia, acute myelogenous leukemia, chronic lymphocyticleukemia, or mast cell leukemia.
 41. The method of claim 1, wherein thecancer is lymphoma.
 42. The method of claim 41, wherein the lymphoma isadult T-cell lymphoma, AIDS-related lymphoma, anaplastic large celllymphoma, angioimmunoblastic T-cell lymphoma, B-cell lymphoma, Burkitt'slymphoma, cutaneous T-cell lymphoma, diffuse large B-cell lymphoma,enteropathy-associated T-cell lymphoma, follicular lymphoma,hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin'slymphoma, MALT lymphoma, mantle cell lymphoma, marginal zone B-celllymphoma, precursor T-lymphoblastic lymphoma, primary central nervoussystem lymphoma, primary effusion lymphoma, splenic marginal zonelymphoma, or T-cell lymphoma.
 43. The method of claim 1, wherein thecancer is multiple myeloma.
 44. The method of claim 1, wherein thecancer is brain cancer.
 45. The method of claim 44, wherein the braincancer is glioblastoma multiforme, glioma, visual pathway glioma,gliomatosis cerebri, or oligodendroglioma.
 46. The method of claim 1,wherein the cancer is neuroblastoma.
 47. The method of claim 1, whereinthe cancer is carcinoma.
 48. The method of claim 47, wherein thecarcinoma is acinic cell carcinoma, adenocarcinoma, adenoid cysticcarcinoma, adenosquamous carcinoma, adrenocortical carcinoma, basal cellcarcinoma, carcinoma in situ, carcinosarcoma, choriocarcinoma, embryonalcarcinoma, gestational choriocarcinoma, invasive lobular carcinoma,lethal midline carcinoma, medullary carcinoma of the breast, metastaticurothelial carcinoma, nasopharyngeal carcinoma, renal cell carcinoma,renal medullary carcinoma, signet ring cell carcinoma, small cellcarcinoma, squamous cell carcinoma, transitional cell carcinoma,urothelial carcinoma, or verrucous carcinoma.
 49. The method of claim 1,wherein the cancer is skin cancer.
 50. The method of claim 49, whereinthe skin cancer is melanoma, acral lentiginous melanoma, nodularmelanoma, or uveal melanoma.
 51. The method of claim 1, wherein thecancer is lung cancer.
 52. The method of claim 1, wherein the cancer isprostate cancer.